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ABSTRACT 
Introduction. Staphylococcus aureus is the second most common bloodstream isolate both 
in hospital- and community-acquired bacteremias and it still confers remarkably high mortality, 
especially in endocarditis. The clinical course of S. aureus bacteremia (SAB) is determined by its 
complications, particularly by the development of deep infections due to metastatic spread and 
thromboembolic events. However, injection drug users (IDUs) tend to have fewer complications 
and better prognosis than nonaddicts. The present studies were undertaken to investigate I) 
trends in the incidence, outcome and morbidity of SAB in Finland during 1995-2001, II) whether 
levoﬂ oxacin added to standard treatment of SAB would improve the patient outcome such as 
reduced mortality or complications, III) differences in clinical manifestations and outcome of S. 
aureus endocarditis among IDUs and nonaddicts, and IV) bacterial strains and their virulence 
factors, and host immune responses in order to explain the different prognosis and risk of 
developing endocarditis among IDUs and nonaddicts.
Subjects and methods. Study I was a retrospective epidemiological population-based study, 
in which trends in the age- and sex-speciﬁ c annual incidence, proportion of nosocomial versus 
community-acquired bacteremia, and outcome during 1995-2001 were evaluated in 5045 SAB 
cases. In Study II, 381 consecutive patients with SAB were randomized into two groups receiving 
either standard antibiotic treatment or levoﬂ oxacin added to standard treatment. Primary end-
points were mortality at 28 days and at three months. Clinical and laboratory parameters were 
analyzed as secondary end-points. The study made a post hoc analysis on the effect of rifampicin 
on mortality among patients with a deep infection available. Studies III and IV consisted of 430 
SAB patients followed prospectively for three months. In Study III, all 74 patients with endocarditis 
were included of whom 20 were IDUs and 54 nonaddicts. Mortality and clinical parameters were 
compared between these groups. In Study IV, all 44 IDUs were identiﬁ ed and 20 of them had 
endocarditis. An equal number of nonaddicts were chosen as group matched controls. S. aureus 
isolates were genotyped by pulsed-ﬁ eld gel electrophoresis, and tested for Panton-Valentine 
leukocidin, staphylokinase, protease, and haemolysin production. Acute and convalescent sera 
were tested for antibodies to α-haemolysin (ASTA) and teichoic acid (TAA). 
Results. The annual incidence of SAB in Finland increased signiﬁ cantly from 11 to 17 cases per 
100,000 population during 1995-2001, most distinctly in elderly persons. Nosocomial infections 
accounted for 51% of cases, with no change in their proportion. The 28-day mortality was 
17%, and did not change over time. Mortality increased with age, being highest among persons 
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aged >74 years. The risk of death at seven and 28 days, and at three months was signiﬁ cantly 
higher among nosocomial cases than among community-acquired cases. Additional levoﬂ oxacin 
treatment in SAB did not decrease mortality or the incidence of deep infections, nor did it 
speed up recovery. Deep infection was found in 84% of SAB patients already within one week 
after randomization. Interestingly, mortality for patients with deep infection was signiﬁ cantly 
lower among those who received rifampicin as compared to those treated without rifampicin 
(17% vs. 38%). Endocarditis was more frequently connected to SAB in IDUs. Right-sided 
endocarditis predominated among addicts whereas most of the nonaddicts had left-sided 
involvement. However, IDUs had equally often extracardiac deep infections (85% vs. 89%), 
arterial thromboembolic events (25% vs. 32%), and severe sepsis (45% vs. 52%) as nonaddicts. 
Injection drug abuse in accordance with younger age and lack of underlying diseases were 
associated with lower mortality. Only a small proportion of patients developed any serological 
response in SAB with a deep infection. Interestingly, the initial ASTA titer was more often 
positive among IDUs without endocarditis than those with endocarditis. No individual strain was 
associated with endocarditis among addicts. Characterization of the virulence factors of strains 
did not reveal any differences in IDUs and nonaddicts. However, haemolytic properties were 
found more often among IDUs without endocarditis than with endocarditis.
Conclusions. Staphylococcus aureus bloodstream infections increased in Finland during 
1995-2001. While the increasing in incidence may partly be due to increased reporting, it 
also reﬂ ects a growing population at risk, affected by such factors as high age and/or severe 
comorbidity. However, the outcome of SAB remained unchanged during the seven years period 
and at a lower level than previously reported worldwide. Interestingly, the changes we detected 
in the epidemiology of SAB overall are very similar to those found in countries with a high 
prevalence of methicillin-resistant S. aureus. The trial reported here on levoﬂ oxacin treatment 
comprises one of the largest prospectively followed SAB populations worldwide. Deep infections 
were found in more patients than previously reported suggesting that they should be intensively 
searched for in SAB. Although levoﬂ oxacin added to standard treatment did not improve outcome, 
we found that patients with deep infection had lower mortality when treated with rifampicin 
combination therapy. In contrast to earlier reports in endocarditis, IDUs showed extracardiac 
deep infections and thromboembolic events with the same high frequency as nonaddicts. In 
spite of this, mortality was signiﬁ cantly lower among IDUs in agreement with previous data. 
The studied host immune responses and pathogen characteristics did not seem to explain the 
difference in clinical outcome between IDUs and nonaddicts. Furthermore, serological tests were 
not helpful in identifying patients with a deep infection. 
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1. INTRODUCTION 
Staphylococcus aureus is one of the most important pathogens in community- and hospital-
acquired bacteremias in all age groups. S. aureus bacteremia (SAB) is presently ranked second in 
Finland with approximately 1000 cases annually,1,2 and the prevalence of bacteremic methicillin-
resistant S. aureus (MRSA) infections is less than 3%.2 The clinical course of SAB is determined 
by its complications, particularly by the development of deep infections due to metastatic spread, 
and by thromboembolic events and the high recurrence rate of bacteremia.1,3-7 Furthermore, 
S. aureus has emerged as a leading cause of endocarditis and is observed in 11% to 35% of 
patients with SAB.5-7 Classic risk factors for endocarditis such as rheumatic heart disease are 
being replaced by new ones, including the increased incidence of injection drug users (IDUs), the 
elderly with degenerative valve disease, patients with an intravascular catheter or a prosthetic 
valve, and nosocomial acquisition.1,4,8
Despite the progress of antimicrobial therapy, bacteremia due to S. aureus is still associated with 
mortality ranging from 7% to 39% in recent publications.3,6,9-14 The factors associated with a poor 
prognosis include, in particular, MRSA strains, non-removable infection foci, metastatic foci (i.e., 
deep infections), thromboembolic events and central nervous system manifestations. IDUs tend 
to have a lower mortality rate (from 2% to 12%) than general population.19-21 The better prognosis 
among IDUs is generally thought to be explained by host factors such as younger age, lack of 
valvular or other underlying diseases, and right-sided involvement in endocarditis. 
Bacteremic S. aureus infections are recommended to be treated with intravenous antibiotic 
therapy, which should continue for several weeks in endocarditis or in other deep infections.22,23 
The standard treatment has been based on beta-lactam antibiotics in countries with a 
low prevalence of methicillin resistance. Newer antistaphylococcal agents such as linezolid, 
daptomycin, or quinupristin-dalfopristin have been used in infections caused by MRSA strains 
or strains with reduced susceptibility to vancomycin but no dramatic superiority in comparison 
to the standard therapies was observed in most of the clinical trials.24-26 Combination therapy 
with an aminoglycoside and a beta-lactam is recommended in endocarditis.27,28 According to 
experimental studies and some small clinical trials, rifampicin added to standard therapy in serious 
staphylococcal infections has been observed to be more effective than single drug therapy.29-31 
However, the clinical use of rifampicin has remained controversial and it is recommended variably 
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in deep-seated abscesses, osteomyelitis, prosthetic valve endocarditis and other foreign body 
infections, or because of a poor response to the standard treatment.22,28,32-35 
New ﬂ uoroquinolones with improved activity against gram-positive bacteria have been introduced. 
Levoﬂ oxacin, trovaﬂ oxacin and moxiﬂ oxacin exhibit activity against methicillin-sensitive S. aureus 
with the MIC90 ranging from 0.06 mg/L to 0.5 mg/L.
36,37 In experimental studies they have shown 
an additive effect in combination with semisynthetic penicillin.38 In SAB, most deep infections 
are evident within two weeks after the onset of bacteremia.16,39 These metastatic infections might 
be prevented by early treatment with a bactericidal ﬂ uoroquinolone, which penetrates well into 
tissues. The efﬁ cacy of a ﬂ uoroquinolone added to beta-lactam therapy in SAB has not been 
evaluated in clinical trials. 
The present studies were undertaken to gain information on epidemiology, treatment and 
outcome of SAB. We evaluated retrospectively the trends in the incidence and outcome due to S. 
aureus bloodstream infections in Finland during 1995-2001. We also conducted a prospective and 
randomized multicenter study to ﬁ nd out if newer ﬂ uoroquinolones (trovaﬂ oxacin or levoﬂ oxacin) 
combined with the present antistaphylococcal treatment of SAB would improve the prognosis 
and reduce complications such as deep infections and thromboembolic events. In addition, 
we evaluated risk factors, differences in clinical manifestations and outcome among IDUs and 
nonaddicts in S. aureus endocarditis. Finally, we investigated if the bacterial strains and their 
virulence factors, and host immune responses could explain the different prognosis and risk of 
developing endocarditis among IDUs as compared to nonaddicts. 
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2. REVIEW OF THE LITERATURE
2.1. Epidemiology of invasive Staphylococcus aureus infections
2.1.1. Incidence of Staphylococcus aureus bacteremia and endocarditis
S. aureus is one of the most frequently isolated pathogens in blood cultures in all age groups and it 
accounts for 19% to 25% of all bloodstream infections worldwide.40-43 S. aureus bacteremia (SAB) 
ranks second in Finland with approximately 1000 cases annually, and is caused predominantly 
by methicillin-sensitive strains.1,2 The epidemiology of bloodstream infections due to S. aureus 
has been studied mostly in selected hospitals which may not be representative of all healthcare 
facilities.7-9,44-47 In addition, only a few population-based studies, which identify trends in the 
incidence and outcome of the disease over time and would allow comparisons between countries, 
have been published previously.10,48,49 The age- and sex-speciﬁ c incidence rates have rarely 
been reported.48,50-52 Furthermore, most current population-based studies have focused on the 
contribution of methicillin resistance to morbidity and mortality associated with SAB.15,49,53,54
A recently published nationwide population-based survey in Denmark, a country with a very low 
prevalence of methicillin-resistant S. aureus (MRSA), reported that the incidence of SAB during 
1971-2000 had increased two-fold from 14 to 31 cases per 100,000 population, representing an 
annualized increase of 4%.10 The overall SAB incidence rates in the United States and Australia 
were of a similar magnitude or slightly higher than in the preceding survey47,52 but in Canada, 
Wales and Northern Ireland the rates were much lower (from 10 to 20 cases per 100,000 
population).49,51,53,54 Furthermore, the major increase in incidence has occurred in males and in 
age groups <1 year and >65 years old.10,48-52,55,56 
The incidence of infective endocarditis (IE) has not changed during the past two decades.22,57 
However, the historical predominance of streptococcal endocarditis is being replaced by S. 
aureus valve infection in many regions of the world.21,58-60 A recently published population-based 
study reported that the adjusted annual incidence of S. aureus endocarditis was one to two 
cases per 100,000 population.61 The increased frequency of S. aureus endocarditis is primarily 
a consequence of an increased use of invasive procedures, steadily rising rates of nosocomial 
bacteremia and injection drug abuse, and improvements in diagnostic techniques.21,22,57,58,62-64 
During the recent decades endocarditis has been observed in 11% to 35% of patients with 
SAB,65-68 and more frequently among injection drug users (IDUs) in 35% to 67% of cases.65,69-72 
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Advances in echocardiography and the use of validated diagnostic criteria for IE have also 
contributed to the incidence of endocarditis in SAB patients.73-76 
2.1.2. Community- and hospital-acquired bacteremia
Frequencies of both community- and hospital-acquired SAB have been increasing steadily44,77,78 
although SAB has been predominantly a nosocomial infection over the decades.50,52,79-81 Patients 
with community-onset bacteremia are younger, and have more often unknown infection foci 
and metastatic infections (e.g., endocarditis or osteomyelitis), probably due to a longer duration 
of bacteremia before diagnosis and treatment when compared to patients with nosocomial 
SAB.17,82-85 Patients with hospital-acquired SAB are older and the source of bacteremia is known 
in nearly all patients.17,84 Nosocomial bacteremia is mostly associated with the expanding use 
of invasive procedures, and the presence of prosthetic devices, and intravascular or urinary 
catheters.79,86 Because of the increased use of long-term intravascular devices in patients with 
chronic diseases in non-hospital settings, a new patient group of catheter-related community-
onset bacteremia has emerged.44,76,78 
2.1.3. Methicillin-resistant Staphylococcus aureus
The global emergence of drug-resistant bacteria is a pressing public health problem. Methicillin 
resistance in S. aureus is determined by the mecA gene, which is a part of an additional 
DNA region, the staphylococcal cassette chromosome mec (SCCmec).87 Mechanisms of MRSA 
dissemination are the spread of individual MRSA clones and horizontal transfer of SCCmec 
among S. aureus and other staphylococci.87 Methicillin-resistant strains of S. aureus were ﬁ rst 
reported in 1961, and subsequently outbreaks of MRSA infections occurred worldwide forming 
a signiﬁ cant proportion of all S. aureus isolates in many countries.40,49,86 Widespread antibiotic 
use, presence of intravascular catheter, severe underlying disease, prolonged hospitalization, 
and poor adherence to infection control precautions have contributed to the rise in MRSA 
rates.76,78,88 
The incidence and prevalence of MRSA varies widely between countries, regions and even 
hospitals.54,89,90 In a survey from the SENTRY Antimicrobial Surveillance Program, geographic 
variations of MRSA prevalence from all sites of infections were found, as follows: Western Paciﬁ c 
region 46%, Latin America 35%, United States 34%, Europe 26%, and Canada 6%.40 In Europe, 
the proportion of MRSA rates ranged from ≤2% to 54%, and among Western Paciﬁ c countries 
from 24% to 70%.40,89 Finland is a country with a very low prevalence of methicillin resistance. For 
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many years prevalence of MRSA was less than 1% among invasive infections. However, during 
2004 increased incidence in the number of MRSA bacteremias was observed but its prevalence 
still remained below 3%.2,90,91
MRSA has been originally conﬁ ned to nosocomial infection, with only rare community-associated 
cases. The prevalence of hospital-acquired MRSA isolates increased progressively in the United 
States from 2% in 1975 to 35% in 1991.92 The rate among bloodstream MRSA isolates during 
1997-1999 was even higher, up to 45%.40 MRSA has accounted for over 60% of all isolates 
in intensive care units (ICU) in the United States, especially among older patients.93 However, 
a major change in the epidemiology of staphylococcal infections is the rapid emergence of 
community-acquired MRSA strains which frequently produce dangerous exotoxins (e.g., Panton-
Valentine leukocidin).94,95 According to a recent meta-analysis,96 the pooled prevalence rates 
of community-associated MRSA isolated from hospitalized patients were 30% to 37%. These 
infections usually involve the skin, and outbreaks have been described among prisoners or IDUs, 
and among patients without established risk factors such as young children, military recruits, or 
competitive sports participants.97-99 
Generally, nosocomial MRSA isolates are multiresistant and clonal, whereas community-
associated MRSA strains are pauciresistant and more polyclonal.86 Glycopeptide agents have 
been considered effective antibiotics against multidrug-resistant S. aureus. Therefore, reports of 
staphylococci with reduced susceptibility to these agents are alarming. The ﬁ rst clinical isolate 
of vancomycin-intermediate S. aureus was described in Japan in 1997,100 and since then these 
strains have continued to cause healthcare-associated infections worldwide. More recently, there 
have been single reports of vancomycin-resistant S. aureus infections which have not been 
observed in Finland.104,105
2.2. Risk factors for Staphylococcus aureus bacteremia
Staphylococcus aureus colonization
Many healthy adults are persistently or intermittently colonized with S. aureus in their anterior 
nares. Approximately 20% of individuals are persistent nasal carriers, 30% are intermittent 
carriers, and 50% are non-carriers.106,107 Nasal carriage of S. aureus is one of the most important 
risk factors for nosocomial and surgical site infections.86,107 Some subgroups such as IDUs, 
patients undergoing hemodialysis or peritoneal dialysis, and patients with diabetes, human 
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immunodeﬁ ciency virus (HIV) or recurrent skin infections are at increased risk for skin and nasal 
colonization with S. aureus.108-112 Studies among IDUs have shown that injection of contaminated 
drug and inhalational drug use may support nasal S. aureus colonization, probably by damaging 
the nasal mucosa.63,113 
In recently published studies, nearly 80% of nosocomial SAB were due to the same phage type of 
S. aureus strain isolated from the patients` anterior nares.107,114 Decolonization with mupirocin has 
been shown to prevent staphylococcal disease in dialysis and surgical patients.115,116 However, 
recent clinical trials in non-surgical and orthopedic patients uniformly failed to conﬁ rm these 
results.117,118 
Comorbid conditions and predisposing factors
Several factors have been suggested to increase the risk for invasive S. aureus infections. A high 
proportion of patients with SAB have underlying diseases such as cardiovascular disease, chronic 
obstructive pulmonary disease, diabetes mellitus, malignancy, chronic renal failure, HIV infection, 
or hepatic cirrhosis.1,51,84,119-121 Only 3% to 5% of patients have had no underlying disease.1,84 
Furthermore, recent surgery, prosthetic devices, or the presence of intravascular catheters are 
important risk factors.76 Older age (>60 years), male sex, alcohol abuse, hyponatremia, anemia, 
immunosuppressive treatment, injection drug use, preceding trauma, previous hospitalization, or 
prolonged treatment in ICU predispose to SAB.28,44,51,79,119,120,122 Patients with chemotactic defects 
(e.g., Job`s syndrome) and defects in phagocytosis are also at increased risk for staphylococcal 
disease.86 
Risk factors for endocarditis and complicated bacteremia
Historically, most cases of IE have occurred in association with community-acquired SAB.84,123 
Underlying cardiac diseases have remained one of the most important risk factors for 
endocarditis among patients with SAB.124 Classic risk factors such as rheumatic heart disease 
are now being replaced by new ones, including IDUs, elderly patients with degenerative 
valve sclerosis, hemodialysis patients, and patients with an intravascular catheter or prosthetic 
valve.21,65,86,125,126 In addition, previous IE, mitral valve prolapse, unknown portal of entry, 
immunosuppression, and hospital-acquired bacteremia have been related to predisposing 
conditions for endocarditis.26,57,58,65,127,128 
A variety of strategies have been used in attempt to identify patients who develop metastatic 
infections secondary to SAB. In recent studies, the most important risk factors for complicated SAB 
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were community-acquisition, hemodialysis,79,130 one or more underlying diseases,128 persistent 
bacteremia or fever for more than 72 hours,16,65,131,132 C-reactive protein (CRP) level >100 mg/L,128 
the presence of a permanent foreign body,79 or a failure to remove an infected catheter.79,133 
The impact of MRSA in complicated SAB has been evaluated in some studies. Patients with 
MRSA bacteremia did not have a higher rate of metastatic infections,6,16,134,135 although in one 
study methicillin resistance was independently associated with an increased risk for metastatic 
infections in intravascular catheter-associated SAB.79 The genetic properties of MRSA isolates 
may produce more virulent phenotypes in cases of catheter-associated bacteremia. Treatment of 
MRSA-infected patients with vancomycin has also been related to clinical failure and prolonged 
bacteremia.136,137 
2.3. Clinical manifestations in Staphylococcus aureus bacteremia
2.3.1. Classiﬁ cation of infection foci 
The initial infection focus for SAB is most often skin or soft tissue infection such as a wound 
or furuncle. From this local infection, the bacteria will spread superﬁ cially, and a bloodstream 
infection may follow.119 Virtually every organ may be infected by S. aureus.32 However, varying 
deﬁ nitions of the infection foci are used in the literature. Nolan and Beaty ﬁ rst proposed 
that infection foci in SAB can be divided into two groups.123 Criteria were established for the 
designation of lesions in various body sites as primary (i.e., portal of entry) or secondary foci 
(i.e., metastatic infection) (Fig. 1). 
Figure 1. Infection foci of Staphylococcus aureus. A primary S. aureus infection may 
 lead to bacteremia resulting in a secondary infection.120
A localized skin lesion or other superﬁ cial staphylococcal infection are considered as a source 
(primary focus) for SAB if signs and symptoms, and physical ﬁ ndings of this infection precede 
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Postoperative wound 
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the bacteremia.123,128,138 The presence of an intravenous catheter has been recognized as a portal 
of entry.8,84 Respiratory and urinary tracts are considered as primary foci for SAB when the 
signs and symptoms of infection typically associate with the bacterial culture results.8,123,139,140 
Furthermore, when the portal of entry is unknown, SAB is deﬁ ned as primary.84 However, the 
absence of a clinically identiﬁ able source for SAB has been thought to be an important predictor 
for metastatic infections.84,123 
Endocarditis, osteomyelitis, septic arthritis, and meningitis are always categorized as secondary 
foci caused by hematogenous spread of SAB, unless there is evidence of direct inoculation 
of the bacteria like surgery or trauma.7,17,121,123 Isolation of S. aureus from urine is considered 
secondary to SAB,141 if the phage type of the organisms isolated from urine and blood matches.84 
Pneumonia can also be hematogenous when caused by embolization of infected thrombotic 
material from tricuspid vegetations.8 In addition, deep-seated abscess and infection of permanent 
foreign bodies are generally classiﬁ ed as metastatic infections (i.e., secondary foci).11,16,79,128,142 
In some studies, SAB has been classiﬁ ed as uncomplicated or complicated. Uncomplicated SAB 
is deﬁ ned as catheter-associated bacteremia or other than catheter-related bacteremia when 
there is no evidence of secondary foci or recurrent SAB within three months.16,79 Complicated 
SAB has been considered as bacteremia with secondary foci or recurrent SAB within three 
months, and/or with other clinical ﬁ ndings such as shock, adult respiratory distress syndrome 
(ARDS), disseminated intravascular coagulation (DIC), acidosis, involvement of central nervous 
system (CNS), or evidence of an embolic or autoimmune event.1,9,16,39,129,143 
It may be difﬁ cult to distinguish between primary and secondary foci, or whether SAB is 
uncomplicated or complicated. In one review, infections caused by S. aureus were deﬁ ned 
as cutaneous and deep infections.32 These deep infections consisted of e.g., bacteremia, 
osteomyelitis, septic arthritis, deep-seated abscess, endocarditis, pneumonia, and foreign body 
or CNS infection to replace classiﬁ cation for secondary foci. The deﬁ nition for deep infections 
described above was used in our trials.
2.3.2. Frequencies of infection foci 
In many articles, primary foci have been combined together as a group and have not been 
separated. The frequency of primary foci varies from 35% to 85% of cases according to different 
studies.1,8,84,143,144 In addition, the source of SAB is unknown in 2% to 58% of patients, suggesting 
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that S. aureus may invade the bloodstream without clinically superﬁ cial infection.6,7,16,65,143 The 
reported frequency of metastatic infections in SAB varies widely from 10% to 53%.16,84,121,145 
These different observations might be partly explained by underdiagnosis or different deﬁ nitions 
of the metastatic infections such as secondary foci, complicated bacteremia or deep infections.124 
Metastatic infections have usually been diagnosed within the ﬁ rst two weeks, and even 74% of 
them are already present at the time of hospitalization.16,39 
2.3.3. Skin and soft tissue infections 
Intact skin is normally an excellent barrier against S. aureus, but when this barrier is broken or 
foreign body implanted, infection can easily be established.119 When bacteria have penetrated into 
the skin, they can disseminate to more profound, normally sterile sites. The typical pathological 
ﬁ nding of staphylococcal disease is a pyogenic exudate or an abscess. S. aureus infections 
of the skin and soft tissues are classiﬁ ed according to the anatomic structure: (1) infection of 
the epidermis is represented by impetigo; (2) infection of the superﬁ cial dermis by folliculitis; 
(3) infection of the deep dermis by furuncles, carbuncles, and hidradenitis suppurativa; and 
(4) infection of subcutaneous tissues by erysipelas, cellulitis or fasciitis with increasing depth 
of infection.86,146,147 Furthermore, S. aureus is a major cause of surgical wound infections in 
hospitalized patients,148 and soft tissue abscesses are the most common complications among 
IDUs.113 
2.3.4. Catheter-related bacteremia 
The presence of a central venous catheter is an important risk factor, with up to 56% of all 
episodes of bacteremias originating from intravascular catheters, especially in hospitalized 
patients.11,149 The presence of a permanent foreign body (i.e., either intravascular or non-catheter 
device), hemodialysis dependence, and methicillin resistance of the S. aureus strain have 
shown an increased risk for metastatic infections and treatment failures in catheter-associated 
SAB.11,79,142 Therefore, current guidelines suggest that non-tunneled central venous catheters 
should be removed immediately when they are found to be the source of SAB.11,79,133,150 A 
tunneled (i.e., Hickman catheter) or implantable device should be removed if there is purulence 
or erythema at the exit site or along the tunnel, evidence of a pocket infection, or if it is associated 
with a complicated deep-seated infection.146 In a meta-analysis of intravascular catheter-related 
SAB, 24% of patients developed metastatic infections or relapses.151 Persistent bacteremia or 
fever for more than 72 hours after removal of the catheter have been related to secondary 
foci.16,152 
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Although the potential association between catheter-related SAB and endocarditis has been 
recognized for decades, the clinical signiﬁ cance of this phenomenon has only recently 
become more evident. The incidence of S. aureus endocarditis in bacteremic patients with 
central intravenous catheter varies widely from 23% to 61%.12,124,153 Fowler et al recently 
showed that 23% of patients with catheter-associated SAB had an endocarditis documented 
by transesophageal echocardiography (TEE) in the absence of clinical or transthoracic 
echocardiographic ﬁ ndings.153 
2.3.5. Endocarditis 
Diagnostic criteria 
Various diagnostic criteria have been established for endocarditis. In the literature before 1960, 
endocarditis was associated with SAB in 64% of cases.121,154 In these studies, the diagnosis of 
IE was conﬁ rmed by autopsy in many instances. In 1976, Nolan and Beaty reported criteria for 
predicting the presence of endocarditis in patients with SAB. According to them, endocarditis 
was more likely in (1) community-acquired bacteremia, (2) when the focus was unknown 
and (3) when metastatic infections were present.123 In 1981, modiﬁ ed criteria by von Reyn 
and coworkers improved the diagnostic speciﬁ city in endocarditis,155 but these criteria did not 
use echocardiographic ﬁ ndings in the case deﬁ nitions. In 1994, new diagnostic Duke criteria 
based on a combination of histopathology, microbiological and echocardiographic imaging were 
introduced.156 These criteria stratiﬁ ed patients with endocarditis as deﬁ nite, possible or rejected. 
However, a modiﬁ ed version of the Duke criteria with deﬁ nite or possible IE was proposed in 
2000 to detect more accurately an endocarditis in S. aureus-associated bacteremia.22,62,75
Echocardiography has become widely used to determine the diagnosis of endocarditis. 
Transthoracic echocardiography (TTE) is recommended for high-risk patients with endocarditis 
such as community-acquired SAB, injection drug abuse, valvular heart disease, prior IE, an 
unknown source of infection, and persistent bacteremia.60,65,69 The overall sensitivity of TTE in 
detecting vegetations may be less than 60% to 70%.157-160 Because of the limited sensitivity of 
TTE, a negative result cannot exclude the diagnosis of IE. 
TEE is more expensive and invasive, but it has increased sensitivity for detecting vegetations of 
75% to 95% but still maintains speciﬁ city of 85% to 98%.126,160 In most studies of SAB, TTE has 
been performed in a high proportion of patients ranging from 49% to 76%, whereas only 12% 
to 42% of patients underwent TEE.7,16,60,128 Fowler et al showed that vegetations were seen only 
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by TEE in 56% of patients with endocarditis due to SAB,12 and therefore the initial use of TEE 
is recommended in patients in the presence of prosthetic cardiac valves or other permanent 
cardiac devices, catheter-associated bacteremia, and a suspicion of cardiac complications such 
as abscesses.76,126,153,157,161 
Clinical picture of Staphylococcus aureus endocarditis 
The clinical picture of endocarditis is complex and can be divided into following processes: 
(1) valve infection and local cardiac complications; (2) extracardiac deep infections such as 
metastatic foci; (3) septic embolism to any organ; and (4) circulating immune complexes.162 
Endocarditis in SAB is characterized by a rapid onset with high fever and the absence of 
physical ﬁ ndings of IE on the initial presentation in contrast to subacute endocarditis caused by 
streptococci.28,76,157 Patients with S. aureus endocarditis may respond slowly and become afebrile 
not until ﬁ ve to seven days after the institution of therapy. In acute native valve endocarditis, heart 
murmur is noted in only 45% of cases on initial evaluation.157 The mean duration of symptoms 
before therapy in S. aureus endocarditis is only three days.11,163 Myocardial abscesses, purulent 
pericarditis, and valve ring abscesses are common local cardiac complications.164 Extracardiac 
deep infections have been associated with SAB in left-sided endocarditis with an incidence 
ranging from 40% to 76%.12,67,69,164
Congestive heart failure and systemic embolic events have the greatest inﬂ uence on the prognosis 
of endocarditis. Systemic thromboembolic events (e.g., spleen, kidney, liver, or cerebral) occur 
in 21% to 50 % of patients, especially among those with left-sided involvement and prosthetic 
heart valve.68,126,165-170 In addition, mitral valve involvement and large vegetations (>10 mm) have 
been associated with an increased risk for embolization.166,171 Most systemic thromboembolic 
manifestations are observed on presentation or within the ﬁ rst two weeks, and the occurrence of 
vascular phenomena decreases after initiation of effective antibiotic therapy.27,165,172,173 Cerebral 
emboli or ischaemic stroke may result in hemiparesis, whereas mycotic aneurysms are usually 
silent, but can lead to intracerebral or subarachnoid hemorrhage.162
The peripheral septic embolic manifestations in endocarditis are most frequently petechiae and 
occasionally Janeway lesions, which are painless, and hemorrhagic spots found on the palms and 
soles.126,157 Renal insufﬁ ciency can be a result of immune complex-mediated glomerulonephritis 
and occurs in less than 15% of patients with IE.157 Other immunological phenomena such as 
Osler`s nodes (tender, subcutaneous nodules in ﬁ ngers and toes) and Roth`s spots (retinal 
hemorrhagic lesions) are also observed in endocarditis.126,164 
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The clinical picture of endocarditis in nonaddicts differs from that in IDUs regarding different 
location of infection, clinical manifestations and prognosis.120 Nonaddicts have more often an 
underlying heart disease, most patients are older than 50 years, and S. aureus primarily involves 
the left side of the heart in 80% of nonaddicts.60,162 Furthermore, the mitral valve is affected more 
frequently than aortic valve, and only a few patients have right-sided endocarditis, or both mitral 
and aortic valve involvement simultaneously.12,60 
In a recent multicenter survey published in 2005, 81% of cases with S. aureus endocarditis had 
native valve involvement, whereas prosthetic valve was involved in 17% of cases.18 However, the 
risk of endocarditis in patients with a prosthetic valve who develop SAB is high, up to 51%.174,175 
The overall risk is similar for both  mechanical and bioprosthetic valves as well as for aortic and 
mitral valve prostheses.174,176 Prosthetic valve infection has been called early when symptoms 
begin within 60 days of valve surgery and late with onset thereafter.157 The risk of development 
of prosthetic valve infection has been thought to be highest within the ﬁ rst three months after 
operation,177 but in one study the risk was independent of the age of the cardiac valve device.174 
The clinical features of prosthetic valve infection are similar to those in native valve endocarditis 
with left-sided involvement although the risk for thromboembolic events is higher in prosthetic 
valve endocarditis.172,177
2.3.6. Bacteremia and endocarditis in injection drug users
S. aureus is the most common cause of bacterial infections among IDUs.18,178 S. aureus 
infections in addicts range from cutaneous soft-tissue abscesses to life-threatening bacteremia 
or endocarditis.178,179 IDUs are more likely to develop bone and joint infections, particularly 
vertebral osteitis, than nonaddicts.63,179 The factors that seem to contribute to the high prevalence 
of staphylococcal disease among IDUs include the pathogen, the host, the drug, the drug-use 
environment, and drug using habits.113,179 The source of S. aureus may be endogenous (the drug 
user´s own ﬂ ora) or external (contaminated drugs, drug adulterants, or paraphernalia).180-183 
Colonization with S. aureus, injection of heroine or cocaine, HIV infection, history of previous IE, 
or skin abscesses have been recognized as risk factors for endocarditis among IDUs.178,184-187 
Most addicts with IE are younger than 40 years of age with male sex predominance.18,21,64,71 
Almost two thirds of IDUs have no history of severe underlying conditions or predisposing heart 
diseases.19,27,71,188,189 
A variety of theories have been proposed to explain the increased prevalence of right-sided 
endocarditis among IDUs but still there is limited understanding of its pathogenesis. Potential 
explanations include damage to right-sided endothelium by repeated exposure to injected 
- 24 -
particulate matter, vasospasm and inﬂ ammation caused by injected diluents or drugs. Furthermore, 
drug-induced pulmonary hypertension with increased right-sided intracardiac turbulence or 
factors relating to the microorganism itself have also been thought to explain the common right-
sided involvement in IDUs.179,190,191 
The tricuspid valve is affected in 70% to 90% of cases among IDUs followed by the mitral 
and aortic valves.19,20,22,71,186,192,193 In the literature, the prevalence of left-sided involvement in 
addicts has ranged from 5% to 19%,19,193-195 but in some studies it has been even higher, up to 
57%.20,188,196 Both sides of the heart are involved simultaneously in only a few cases.19,188 S. aureus 
endocarditis in IDUs is reported to be associated less frequently with extracardiac deep infections 
and systemic arterial emboli or strokes, probably due to right-sided involvement.19,21,71,187,194,197 
However, in a previous report there were no differences in maximum temperature, or leukocyte 
count between addicts with and without endocarditis.179 Septic pulmonary embolism occurs in up 
to 87% of cases of right-sided endocarditis18,71,185,188,195 but peripheral septic skin manifestations 
are usually absent in accordance with right-sided involvement.187  
2.3.7. Other deep infections 
Osteomyelitis and septic arthritis
Bone and joint infections are the next most common infection sites caused by S. aureus after skin 
and soft tissue infections.198 Long bones may be involved following hematogenous dissemination 
of S. aureus, but osteitis in these locations is typically a result of contiguous spread from a 
traumatic wound or infected ulcer and is most often seen in diabetics with vascular disease.86 
Acute hematogenous S. aureus osteomyelitis in lumbar or thoracic vertebrae is observed more 
often, in up to 19% of patients, especially among the elderly. Furthermore, a paraspinous or 
epidural abscess is frequently associated with the vertebral osteomyelitis.
Septic arthritis is generally a result of surgical intervention and hematogenous spread or may 
be iatrogenic in the case of joint puncture or arthroscopy.17,201 The most common joints during 
the course of SAB are the knee, hip, elbow, shoulder, and interphalangeal joints.17 The risk of 
joint infection among patients with SAB increases in those who are immunosuppressed or have 
rheumatoid arthritis.86 S. aureus is also the most frequent cause of septic arthritis in children.198 
Meningitis
S. aureus meningitis is often a result of trauma, neurosurgical procedure or infection of a 
ventricular shunt. Meningitis due to hematogenous spread is reported in only 1% to 9% of 
bacteremic cases.1,12,16,134,202,203 Meningitis caused by staphylococcal bacteremia is usually a part 
of disseminated infection with other secondary foci such as endocarditis or osteomyelitis.86,162 
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Patients with hematogenous meningitis are older, have chronic underlying diseases, and their 
prognosis is poor with a high mortality rate of 56%.203 
Pneumonia
Pneumonia due to S. aureus constitutes 1% to 10% of cases of community-acquired 
pneumonia204-206 and up to 30% of cases of nosocomial pneumonia.207 Pneumonia may be 
caused by aspiration or hematogenous spread due to a release of infected thrombotic material 
from the venous system or from infected tricuspid vegetations frequently seen in IDUs.120,208 In 
recent studies, pneumonia during the course of SAB is observed in 6% to 34% of patients.7,8,121,144 
A necrotizing pneumonia related to the toxin-producing Panton-Valentine leukocidin (PVL) strain 
is a new entity. It occurs in healthy children and young adults, may rapidly progress to acute 
ARDS, and carries a high mortality rate.209 
Urinary tract infection
S. aureus can cause ascending urinary tract colonization, and primary infection is observed mainly 
among long-term care patients.140 Persistent urinary staphylococcal colonization is associated 
with high risk of bacteremia. Therefore, it is important to recognize predisposing factors for 
primary staphylococcal bacteriuria which include nosocomial causes (e.g., indwelling catheters 
or surgery) and obstructive disease (e.g., prostatic hyperplasia or stricture).210 Paradoxically, S. 
aureus bacteriuria can be a consequence of bacteremia with secondary hematogenous spread 
to the kidneys reported in up to 7% of SAB.8,140,211,212 Risk factors for S. aureus bacteriuria 
secondary to SAB are chronic underlying diseases like diabetes and cancer, or hemodialysis, 
injection drug abuse and the presence of foreign bodies.8,210 
Virtually any organ may be infected by S. aureus due to hematogenous dissemination. Other 
common deep infections such as deep-seated abscesses, pleural empyema, mediastinitis, 
pericarditis, septic bursitis, pyomyositis, or septic thrombophlebitis can occur as clinical 
manifestations during the course of SAB.86 
Foreign body infections 
An increasing number and variety of prosthetic devices are presently implanted in patients, and 
S. aureus is the second leading cause of prosthetic joint infections after coagulase-negative 
staphylococci.213,214 In a recent study, 42% of orthopedic devices and 45% of cardiac devices 
(e.g., cardiac pacemaker or implantable cardioverter-deﬁ brillator) were infected in patients with 
SAB.215 In addition, the incidence of other deep infections (i.e., endocarditis, osteomyelitis, 
and deep-seated abscesses) was as high as 49% in patients with an orthopedic device.215 
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Hematogenous seeding from a remote infection focus is a relatively rare mechanism of vascular 
graft infection with the highest risk during the ﬁ rst four to six postoperative months.214 
2.4. Mortality in Staphylococcus aureus bacteremia 
2.4.1. Predictors for mortality and poor prognosis 
The mortality of SAB was extremely high up to 82% in the preantibiotic era (Fig. 2).216 Later, 
between 1950 and 1990, the mortality rate decreased and varied in different surveys from 24% to 
58%.5,122,217-220 Today, the mortality of SAB is lower, but still high ranging between 7% to 39%.3,6,9-14 
A variety of deﬁ nitions based on either clinical judgments and/or time from SAB to death has 
resulted in a wide range in mortality. The low mortality rates have been based on the deﬁ nition 
of death within seven days after the onset of SAB including clinical or microbiological evidence 
of S. aureus infection at the time of death (i.e., mortality due to SAB).12,45,221,222 In other studies, 
higher mortality rates have been reported within two to ﬁ ve weeks after the onset of bacteremia 
(i.e., in-hospital or overall mortality).3,7,8,120,135 
Figure 2.  Mortality rate of Staphylococcus aureus bacteremia at various time points.8,10,121 
Some data suggest that hospital-acquired bacteremia is associated with higher death rates.3,5,80 
This might be due to older age and more severe comorbid conditions in hospitalized patients. 
However, the overall mortality in many recent studies has been shown to be approximately similar 
both for community-acquired and nosocomial cases.7,8,12,83,85 Serious underlying diseases,14,84,121 
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age over 60 years,7,10,123 severe sepsis,1,68 persistent bacteremia,65 inapproriate empirical antibiotic 
treatment and failure in eradication of an infection focus have been associated with higher 
mortality in SAB.3,6,8,14,17 Even less potent or too short treatment might carry a risk for a poor 
prognosis. According to a recent study,8 a total daily dose <4 g of dicloxacillin sodium and 
the duration of antibiotic treatment for less than 14 days were signiﬁ cantly related to fatal 
outcome. Higher mortality has been observed also in patients with thromboembolic events and 
deep infections,16,18 such as pneumonia, meningitis and endocarditis.5,7,10,13,134 Furthermore, an 
unknown source of SAB has been identiﬁ ed an independent risk factor for death.3,7,145 The 
high level of Acute Physiology and Chronic Health Evaluation (APACHE II) score in SAB was 
recently found to predict for poor prognosis.7,144,223 Other factors associated with fatal outcome 
include hyperbilirubinemia (>40 µmol/L), elevated level of serum creatinine (≥200 µmol/L), 
thrombocytopenia (<100 x 109/L), acidosis (blood pH<7.3), leukocytosis or leukopenia (>10.0 x 
109/L or <3.0 x 109/L), and granulocytosis or granulocytopenia  (>8.0 x 109/L or <1.0 x 109/L).1,5 
2.4.2. Catheter-related bacteremia
An increasing percentage of SAB is related to catheterization.11,149 The mortality rate in intravenous 
catheter-associated SAB has generally been low ranging from 5% to 10% but in some studies up 
to 33%.39,144 According to a current meta-analysis,151 the pooled mortality rate for catheter-related 
SAB was 15% regardless of duration of therapy. 
2.4.3. Endocarditis among nonaddicts
The overall mortality in patients with S. aureus endocarditis is high varying between 30% to 
46%,18,60,65,66,143,224 but an even higher rate of 71% was published in 1986.124 Higher mortality has 
been associated with left-sided involvement, older age, rapidly fatal underlying diseases, pre-
existing heart valve diseases, renal failure, severe sepsis, prior hospitalization within 30 days of 
onset of SAB, persistent bacteremia, and the presence of a prosthetic valve.7,21,65,68,189,224,225 In 
a recent study on 566 patients with native valve S. aureus endocarditis,18 additional important 
predictors for mortality were heart failure, formation of periannular abscess, aortic or mitral valve 
vegetations, CNS thromboembolic manifestations and absence of surgical therapy.
The prognosis of prosthetic valve endocarditis has improved since the 1990s, although the 
mortality is still about 50%.76,174 Improved survival has been related to many factors, including 
early surgical intervention, recognition of the need for multidrug therapy, use of TEE for early 
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identiﬁ cation of endocarditis and cardiac complications, and improvements in the management 
of critically ill patients hospitalized in ICUs.174,177
2.4.4. Endocarditis associated with injection drug abuse
In the past two decades, endocarditis has become one of the most prevalent causes of death in 
IDUs. However, the mortality of S. aureus endocarditis among this patient group is remarkably low 
varying between 2% to 12%.19-21,189,193,224 The favourable outcome in addicts is still not completely 
understood but is generally explained by host factors such as younger age, lack of pre-existing 
heart disease or other underlying diseases, and right-sided involvement.18,19,21,157,190,224 The latter 
factor is supported by ﬁ ndings of better sterilization of right-sided valve vegetations in experimental 
endocarditis as compared to left-sided valves.226,227 Furthermore, the density of bacteria in infected 
tricuspid vegetations was smaller as well. Only addicts with ARDS, tricuspid valve vegetations over 
2 cm in size and left-sided involvement have had higher mortality ranging from 20% to 33%.76,185,228 
In addition, IDUs with severe immunosuppression such as acquired immunodeﬁ ciency syndrome 
(AIDS) present a fatal outcome more frequently than in immunocompetent patients.195 
2.4.5. Bacteremia due to methicillin-resistant Staphylococcus aureus
The contribution of methicillin resistance to the morbidity and mortality in SAB is controversial. 
In a recent meta-analysis15 and in some well-designed studies,3,65,134,229 MRSA bacteremia was 
signiﬁ cantly associated with higher mortality than bacteremia caused by methicillin-sensitive S. 
aureus (MSSA) strains. Furthermore, patients with endocarditis due to MRSA are signiﬁ cantly 
more likely to have persistent bacteremia than those with endocarditis caused by MSSA.21,65 
However, several other studies suggest that MRSA bacteremia is not associated with increased 
risk for death.6,7,14,43,135,230 Because patients infected with MRSA tend to be older,3,45 have more 
often severe underlying diseases,6 septic shock or pneumonia3 than patients infected with 
MSSA, evaluations on the impact of MRSA on patient outcome should be adjusted for these 
confounding factors.16,135,231 Therefore, the association between MRSA and mortality may be 
partially explained by inherent differences between the patient groups rather than methicillin 
resistance itself. Speciﬁ cally, the difference in mortality between MRSA and MSSA may only be 
evident in certain subset of patients, such as severely ill ICU patients.229,230 In addition, different 
antibiotics are used to treat MRSA and MSSA infections,230 and patients with MRSA are at 
increased risk for delayed therapy.232 Some clinical evidence suggests that vancomycin would 
be inferior to beta-lactam antibiotics in the treatment of serious staphylococcal infections such 
as endocarditis.136,137 Furthermore, a growing amount of evidence suggests that accessory gene 
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regulator (agr) group II polymorphism in MRSA might be predictive of failure of vancomycin 
therapy.233
2.5. Recurrence of Staphylococcus aureus bacteremia
Recurrent SAB is a common phenomenon. A second episode of SAB may represent as a relapse 
conﬁ rmed by the same resistance pattern and pulsed-ﬁ eld gel electrophoresis (PFGE) type of the 
two consecutive infecting S. aureus strains, or as a reinfection unrelated to prior staphylococcal 
infection.234 Recurrent episodes of SAB have ranged from 9% to 23% in studies with a median 
follow-up time of three to six months.6,8,11,13,16,65,235 According to a recently published study,235 
relapse of SAB after completion of antibiotic therapy occurred earlier than reinfection (median, 
36 versus 99 days).
Recurrences of SAB are primarily relapses and are associated with an unremoved foreign body, 
hemodialysis, native heart valve endocarditis, liver cirrhosis, and vancomycin therapy.150,189,234-236 
Vancomycin treatment may also predispose to prolonged bacteremia.237 Furthermore, a total 
daily dose of dicloxacillin less than 3 g, short duration of therapy in SAB with deep infections, 
persistent bacteremia over three days, and underecognition of osteomyelitis or endocarditis are 
all risk factors for a recurrent SAB.8,13,16,129,235,238 Recurrent endocarditis is common especially 
in addicts, and the median interval between episodes is far shorter among IDUs compared 
with nonaddicts.170 Thus, all patients with relapsing SAB are recommended to undergo TEE.235 
Recent studies have also demonstrated that consultation of an infectious disease specialist can 
improve remarkably the clinical outcome and reduce the number of relapses for patients with 
SAB.7,11,84,143 
2.6. Treatment of Staphylococcus aureus bacteremia
2.6.1. Standard antibiotic therapy
In Finland, the frequency of bacteremic MRSA infections is less than 3%,90,91 and therefore the 
parenteral semisynthetic penicillins (cloxacillin or dicloxacillin) constitute the basis of standard 
therapy in SAB.28,239 The usual dose in adults is 2 g of oxacillin or dicloxacillin every four to six 
hours.24,26 Such doses of dicloxacillin can cause signiﬁ cant thrombophlebitis and administration 
through a central venous line is usually necessary. When patients have penicillin allergy without 
anaphylaxis, ﬁ rst- or second-generation cephalosporins, or clindamycin can be used.26,62,157 
Clindamycin is bacteriostatic and related to an increased risk of relapses, and therefore it is 
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not recommended for treatment of endocarditis.120,240 Instead, it can be used in osteomyelitis 
due to its excellent bone penetration.50 Vancomycin has been associated with a high frequency 
of clinical failures in several studies,11,235,241-243  although this ﬁ nding is controversial.16 Thus, 
vancomycin should be used only in MRSA strains or in patients intolerant or allergic to penicillins 
and cephalosporins.13,244 Experience with newer antistaphylococcal agents (e.g., linezolid, 
quinupristin-dalfopristin, daptomycin, or tigecycline) is still limited, especially in endocarditis, and 
their ability to prevent persistance and relapse of SAB is unknown.27,237,245,246 These antibiotics are 
indicated for the treatment of MRSA infections and patients who are infected with a strain having 
reduced susceptibility to vancomycin, or who fail on or are intolerant of conventional therapy.24,26 
2.6.2. Antibiotic therapy in catheter-related and uncomplicated bacteremia
The most common type of uncomplicated SAB is catheter-related bacteremia. The standard 
antibiotic treatment consists of a beta-lactam based regimen as monotherapy in patients with 
bacteremia due to MSSA.242 The optimal duration of antibiotic therapy for central intravenous 
catheter-associated bacteremia has been controversial and questioned for decades. However, 
recent studies have suggested that the risk for endocarditis and other deep infections in patients 
with localized catheter-related SAB is low enough to recommend short-course parenteral therapy 
(10 to 14 days) when the infected catheter has been removed.121,133,149,161,242,247 Patients with 
predisposing valvular abnormalities, superﬁ cial non-removable infection focus, and persistent 
bacteremia or fever for more than 72 hours after removal of the catheter have more often deep 
infections.16,152,248 In these cases, longer parenteral therapy of four to six weeks is recommended. 
Furthermore, TEE has been shown cost-effective in the evaluation of possible endocarditis and 
in determination of the duration of therapy in catheter-related bacteremia.161,249 For patients 
with uncomplicated SAB other than catheter-related bacteremia, two weeks parenteral therapy 
followed by two weeks oral treatment has been suggested.250,251
2.6.3. Studies on combination antibiotic therapy
Aminoglycoside combined with standard therapy
Data on the effect and recommendations for various antibiotic combinations are variable in 
SAB with metastatic infections. Combination therapy has been used to increase bactericidal 
activity or to prevent development of antimicrobial resistance. Speciﬁ cally, the combination 
of aminoglycosides and beta-lactams produces a synergistic effect and increases bacterial 
killing in vitro and in animal models of S. aureus endocarditis.28,164,252 However, the beneﬁ ts of 
combination therapy with an aminoglycoside have not been convincingly established in human 
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clinical trials. 253-256 In one prospective study consisting of patients with mainly left-sided S. 
aureus endocarditis,257 a more rapid clearance of bacteremia was achieved with the combination 
of gentamycin and nafcillin than with nafcillin therapy alone. However, mortality or cardiac 
complications were not reduced, but in contrast gentamycin-associated nephrotoxicity was 
evoked.
Rifampicin combined with standard therapy
Recommendations for combination therapy including rifampicin are controversial although it is 
widely used in SAB with deep infections and when the response to standard antistaphylococcal 
antibiotic therapy alone is either poor or slow.28,32 Rifampicin shows excellent antistaphylococcal 
activity against MSSA and MRSA strains including penetration into cells and bioﬁ lms, and ability 
to kill phagocytosed bacteria.33,34,239,258 In a recent study, rifampicin effectively eradicated S. 
aureus also in non-phagocytic cells in vitro,259 which is suggested to be valuable in the treatment 
of invasive S. aureus infections. 
Speciﬁ cally, the combination of oxacillin and rifampicin had a synergistic action in vitro when 
the concentration ratio of oxacillin to rifampicin was low, whereas antagonism occurred with 
higher ratios.29 Rifampicin and ﬂ uoroquinolone in combination had also an antagonistic effect 
in S. aureus endocarditis in animals when administrated on short-term treatment (four to six 
days).33,260,261 However, two other experimental animal studies showed improved results with 
combination therapy with rifampicin and nafcillin or vancomycin as compared to single-drug 
treatment in chronic staphylococcal osteomyelitis although the drug combination was antagonistic 
in vitro.262,263 Antagonism between rifampicin and other antimicrobials in vitro has substantially 
hampered the clinical acceptance of rifampicin in the treatment of staphylococcal infections. 
Furthermore, resistance in staphylococci invariably develops during therapy if rifampicin is used 
alone.23,29,264-266 Ideally, the companion drug should exhibit pharmacokinetics similar to rifampicin 
without an antagonistic interaction.267 
Only limited human data are available to support the use of rifampicin in severe S. aureus 
infections. Some small randomized clinical trials suggested that adding rifampicin to semisynthetic 
penicillin in patients with severe S. aureus infections improved clinical cure and bacteriological 
eradication whereas no effect in mortality was seen.30,31,268,269 However, the combination of 
rifampicin and vancomycin in a study of MRSA endocarditis had no signiﬁ cant advantage in 
clinical response over vancomycin alone.137
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Fluoroquinolones in the treatment of staphylococcal infections
The ﬂ uoroquinolones are a relatively new class of antimicrobials with good tissue and intracellular 
penetration, and with an ability to kill intracellular bacteria.37,267,270,271 Fluoroquinolones exhibit 
high serum and tissue concentrations after oral administration, and have a low side-effect 
proﬁ le.272,273 Differences in the activity of the ﬂ uoroquinolones in vitro primarily form the basis of 
their classiﬁ cation. The older ones (e.g., ciproﬂ oxacin, norﬂ oxacin, and oﬂ oxacin) predominantly 
have activity against gram-negative bacteria.37 The newer ﬂ uoroquinolones (e.g., levoﬂ oxacin, 
trovaﬂ oxacin, moxiﬂ oxacin, gemiﬂ oxacin, and gatiﬂ oxacin) exhibit improved activity against gram-
positive organisms and also have improved pharmacokinetic properties allowing dosing more 
seldom.37,270 Levoﬂ oxacin, the L-isomer of oﬂ oxacin, is the least active of newer ﬂ uoroquinolones 
against methicillin-sensitive S. aureus with an MIC90 range of 0.25 to 0.5 mg/L but still 
signiﬁ cantly more active than ciproﬂ oxacin.36 Trovaﬂ oxacin, moxiﬂ oxacin, and gatiﬂ oxacin all have 
shown activity equivalent or superior to levoﬂ oxacin with MIC90 ranging from 0.06 mg/L to 0.5 
mg/L.36,37,274
Early experimental studies showed that ﬂ uoroquinolone monotherapy was curative for many 
cases of staphylococcal infections involving orthopedic implants and that it was also effective 
in MSSA and MRSA endocarditis. Subsequent treatment failures were related to emergence 
of antibiotic-resistant isolates during or after therapy. However, these studies suggested that a 
combination of rifampicin and ﬂ uoroquinolone prevented emergence of resistance. Furthermore, 
combination therapy with a ﬂ uoroquinolone (ﬂ eroxacin plus rifampicin or ﬂ eroxacin plus rifampicin 
plus vancomycin) was observed to be highly effective and superior to single drugs alone 
(ﬂ eroxacin or vancomycin) in treatment of chronic staphylococcal foreign-body infections in a 
rat model.277 Comparative clinical trials are few but they have also demonstrated efﬁ cacy of oral 
ﬂ uoroquinolones combined with either rifampicin or fucidic acid in staphylococcal infections.273 
For severe MSSA infections, combination of a ﬂ uoroquinolone and rifampicin has provided a 
clinical cure without decreased mortality in right-sided endocarditis,278-280 in chronic osteomyelitis 
or in foreign body infections,281,282 and in other deep-seated abscesses.280 
After the introduction of the newer ﬂ uoroquinolones, they were considered as an alternative 
therapy to treat MRSA infections in particular which has, however, been complicated by rapid 
emergence of resistance.283 Up to 80% of MRSA strains have become resistant to ciproﬂ oxacin 
in Europe and the United States,95,284-286 whereas most of the MSSA strains are susceptible to 
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ﬂ uoroquinolones.287,288 The reasons for disparity in rates of ﬂ uoroquinolone resistance between 
MSSA and MRSA strains are uncertain. Cross-resistance among ﬂ uoroquinolones seems to 
be extremely common,267,289 although the newer agents such as trovaﬂ oxacin and gatiﬂ oxacin 
may be active against these resistant strains.24,283 Furthermore, ﬂ uoroquinolone use has been 
reported as an ecologic risk factor for high MRSA prevalence among hospitalized patients, 
and persistent colonization with MRSA.287,290,291 Thus, ﬂ uoroquinolones do not offer in general a 
therapeutic alternative for the treatment of MRSA infections.292 
2.6.4. Recommendations for antibiotic therapy in endocarditis
Left-sided native valve endocarditis
The most recent guidelines recommend a combination of an aminoglycoside with a beta-
lactam or vancomycin for the ﬁ rst three to ﬁ ve days of treatment for left-sided native valve 
endocarditis.22,27,28,76 Aminoglycoside should be administrated in a 3-times-daily dosing regimen, 
with a total daily dose not to exceed 3 mg/kg in patients with normal renal function.27,293 Routine 
use of rifampicin has not been suggested for the treatment of uncomplicated left-sided native 
valve endocarditis in SAB.22,76,126,137,157 However, rifampicin is recommended as an additive 
therapy in those patients who do not respond adequately to conventional treatment or have 
complicated endocarditis (e.g., myocardial or extracardiac deep infections).23,27,35,164,239 There are 
no prospective, randomized, controlled studies to demonstrate the most appropriate duration 
of standard antistaphylococcal therapy.62 Recommendations for treatment duration are largely 
derived from retrospective studies, consensus opinion or previously published recommendations. 
Thus, for patients with uncomplicated left-sided native valve IE, four to six weeks of beta-lactam 
or vancomycin treatment is sufﬁ cient.22,27,126 For patients with complicated endocarditis, six weeks 
of standard antibiotic therapy should be used.27  
Prosthetic valve endocarditis
Staphylococcal infections of prosthetic heart valves due to MSSA or MRSA are recommended 
to be treated with three antibiotics in combination. An aminoglycoside is initiated together with a 
beta-lactam or vancomycin for the ﬁ rst two weeks of therapy.22,27,76,126 If the strain is resistant to all 
aminoglycosides, a ﬂ uoroquinolone (such as moxiﬂ oxacin or gatiﬂ oxacin) to which it is susceptible 
may be used instead of an aminoglycoside.157,177,277,294 However, it should be noted that there is no 
clinical data to support this recommendation. Rifampicin is combined with a standard antibiotic 
for at least six weeks course of therapy in prosthetic valve endocarditis.22,23,126,164,295
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Right-sided endocarditis
Right-sided endocarditis predominates among IDUs and involves a different pathophysiology. It 
is easier to cure and it can heal spontaneously in experimental models.86,226,296 Several clinical 
studies have demonstrated that uncomplicated cases of right-sided endocarditis may be treated 
successfully with only 2-week regimens of a semisynthetic penicillin and aminoglycoside to 
reduce the expense and inconvenience of the four weeks duration of therapy.176,257,297-299 A 
short-course therapy with glycopeptides (vancomycin or teicoplanin) and an aminoglycoside is 
associated with a high rate of clinical and microbiological failure and should not be used.300,301 
The standard 4-week therapy for right-sided endocarditis is recommended in situations of (1) a 
slow clinical or microbiologic response >96 h after initiation of antibiotic therapy; (2) complicated 
right-sided endocarditis with extracardiac deep infections, heart failure, or valve vegetations 
>2 cm; (3) right-sided endocarditis caused by MRSA; and (4) severe immunosuppression or 
AIDS.86,186,191,302 
Uncomplicated right-sided endocarditis among IDUs have been treated successfully with oral 
antibiotic treatment alone.278,279 Heldman and colleagues demonstrated279 that a combination of 
oral ciproﬂ oxacin and rifampicin given for four weeks was as effective as a 4-week regimen with 
parenteral oxacillin plus aminoglycoside. This oral regimen may be a reasonable alternative for 
those IDUs who are unwilling or unable to receive intravenous therapy.62,186
2.6.5. Recommendations for antibiotic therapy in other deep infections
In clinical practice, rifampicin is often suggested to be used in combination with standard 
antibiotic therapy in deep-seated abscesses,32,280 osteomyelitis,35,269 foreign body infections,303,304 
or because of poor response to the standard treatment in SAB.33,34 The optimum duration of  a 
parenteral beta-lactam or vancomycin for invasive (e.g., osteomyelitis or deep-seated abscesses) 
and orthopedic implant-related S. aureus infections is controversial, but it is suggested that 
they should continue for four to six weeks.23,86,273,305 More recently short term parenteral therapy 
followed by prolonged (three to six months) oral therapy with rifampicin plus a ﬂ uoroquinolone 
has been proven to be effective in osteomyelitis and foreign body infections.146,282,304,306,307 If 
conservative treatment fails or removal of infected foreign body material is impossible (e.g., due 
to technical difﬁ culties or severe underlying diseases) lifelong antimicrobial treatment is needed 
and may prevent progression of the infection for many years.214 
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2.6.6. Surgical treatment
Infected foreign bodies in SAB should be removed whenever possible. For patients with an 
eradicable focus, both the mortality and the recurrence rates have been observed signiﬁ cantly 
lower as compared to those patients, in which the focus was not eradicated.8 Surgical treatment 
of patients with infected orthopedic devices include debridement with retention of the prosthesis, 
one- or two-stage exchange, resection arthroplasty, arthrodesis, and amputation.213,303 The use 
of antimicrobial-impregnated cement is suggested.308 In acute osteomyelitis that is unresponsive 
to antimicrobial therapy, surgical decompression may be required.309 Successful surgical therapy 
in chronic osteomyelitis includes debridement of the infected bone and soft tissues and 
revascularization of a poorly perfused region.309 Most abscesses and empyemas require drainage. 
However, there is limited evidence available that some small abscesses in clinically stable 
patients respond to medical therapy without drainage.120,146 
Several studies suggest that patients with staphylococcal endocarditis should be considered for 
valve replacement as an adjunctive therapy because of improved outcome.157,310 The generally 
accepted indications for surgical intervention in endocarditis include congestive heart failure, 
uncontrolled infection, more than one serious systemic embolization, hemodynamically signiﬁ cant 
valvular dysfunction, or local suppurative complications such as perivalvular or myocardial 
abscesses.76,164 Surgical treatment is required in up to 45% of patients with left-sided native 
valve endocarditis.18,169 Because of the high mortality associated with S. aureus prosthetic valve 
IE, early surgical replacement is almost always recommended during concomitant antibiotic 
therapy.174,311,312
Enthuasism for cardiac surgery varies for patients with drug addiction, because there is lack of 
controlled trials upon which to base decision making.302 Furthermore, the surgical approach is 
more conservative among IDUs due to continued use of injecting drugs and higher incidence of 
recurrent IE compared with the general population.186 Cardiac surgery was observed necessary in 
only small minority of narcotic addicts185 although other studies conﬁ rmed that surgical treatment 
clearly improved their survival as well.313 However, indications for valve replacement in left-
sided endocarditis among IDUs are the same as in the general population. Persistent infection 
is the indication for surgery in over 70% of right-sided endocarditis.164 Tricuspid valvectomy or 
vegetectomy with valvuloplasty are the recommended surgical interventions for refractory right-
sided involvement.314,315                  
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2.7. Bacterial strain characteristics and host serological responses in 
 Staphylococcus aureus infections   
2.7.1. Bacterial virulence factors 
Components of the cell envelope
Staphylococcal infections are characterized by penetration by the bacteria from the bloodstream 
into tissues resulting in dissemination, abscess formation and metastatic infection. S. aureus 
is also capable of evasion of phagocytosis by neutrophils.316 Tissue invasion and killing by 
phagocytes are involved in the inﬂ ammatory response that leads to septic shock.317 The virulence 
of S. aureus depends upon the effectiveness of the host defence in recognizing and dealing 
with components of cell wall, expression of a capsule and/or slime layer, and a wide variety of 
bacterial extracellular toxins and enzymes which are important both for the invasiveness as well 
as persistence of bacteria in infected organs.318-320 
The staphylococcal cell wall consists of peptidoglycan, teichoic acid and various proteins, 
called adhesins (Fig. 3). Characteristic features of the peptidoglycans are endotoxin-like activity, 
stimulation of macrophages to release cytokines, activation of the complement cascade and 
aggregation of platelets.28,321 Teichoic acids are likely to serve as bacteriophage receptor sites 
for attachment of cell-wall active enzymes and other proteins, and have recently been shown 
to play a key role for adherence of S. aureus into nasal epithelium.86,322 Teichoic acids also 
activate the alternative complement pathway and the lectin pathway. Lipoteichoic acids are the 
plasma membrane-bound counterparts of teichoic acids. They have been observed to initiate 
inﬂ ammation by triggering the release of cytokines by macrophages. 
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Figure 3. Structure of the cell envelope including the cell wall and cell membrane. 
 Modiﬁ ed from the ﬁ gure by Vidar Bakken.323
Adhesion and invasion
Staphylococci can produce several adhesins or microbial surface components recognizing 
adhesive matrix molecules (MSCRAMMs),28 which are known to mediate staphylococcal adhesion 
to various cell surface proteins like ﬁ bronectin, ﬁ brinogen, collagens, vitronectin, laminin, 
thrombospondin, bone sialoprotein and elastin.324 The effects of binding of these proteins enable 
staphylococci to colonize tissues and initiate infection in wounds, joint cartilage, bones and heart 
valves.28,325,326 Recent obervations on the cabability of S. aureus to invade eukaryotic cells have 
provided new information why antibiotic treatment of staphylococcal infection in many cases fails 
or reactivates due to the fact that the drug given can not reach intracellular bacteria.327 It has 
been demonstrated that S. aureus uses ﬁ bronectin-binding proteins (FnBP) on its surface for 
invasion into mammalian cells and α5ß1-integrin on the surface of the host cell.
328
The slime layer is an extracapsular, polysaccharide structure, which may inﬂ uence virulence by 
increasing bacterial adhesion to endothelial cells and inhibiting phagocytosis.319 Serotype 5 or 
8 capsular polysaccharides compose the majority of all isolates obtained from cases of SAB.28 
Staphylococci have a special tendency to adhere to the polymer surface of plastic material, 
develop microcolonies and produce an extracellular polysaccharide (glycocalyx or slime) which 
forms a bioﬁ lm covering the microorganism.329 The bioﬁ lm protects the bacteria from phagocytosis 
and the action of antibiotics.
teichoic acid
proteinspeptidoglycan
adhesins
polysaccharides
lipoteichoic acid
cell wall
cytoplasmic
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Extracellular enzymes and toxins
S. aureus produces and secretes a number of extracellular enzymes (e.g., staphylokinase, 
protease, coagulase, hyaluronidase and lipase) and toxins (e.g., haemolysins, Panton-Valentine 
leukocidin, enterotoxins, toxic shock syndrome toxin-1 and epidermolytic toxins) which have 
been implicated as potential virulence factors.86,319 Staphylokinase (SAK) is a plasminogen-
activator protein and is responsible for the ﬁ brinolytic activity of S. aureus which has an important 
role in disseminated intravascular coagulation (DIC) in sepsis.319,330 Staphylokinase-plasminogen 
complex may also affect bacterial invasion into the host tissues.331,332 SAK production has been 
connected to uncomplicated bacteremia and better prognosis.333 Additionally, expression of SAK 
may be a requirement for the persistence of staphylococcal nasal carriage.330 These ﬁ ndings 
suggest that SAK is one part of the adaptive mechanisms of S. aureus which favours bacterial 
symbiosis with the host. 
S. aureus has a minimum of four haemolysins of which α-haemolysin is best characterized and 
most potent membrane-damaging toxin. S. aureus α-haemolysin is known to induce apoptosis 
in various cell types including keratinocytes, endothelial (e.g., heart valves) and epithelial cells 
at low concentrations.334 S. aureus produces also three type of proteases which all may be 
responsible, either directly or indirectly, for connective tissue damage.319 
Panton-Valentine leukocidin (PVL) is a cytotoxin, which exhibits highly speciﬁ c lytic activity on 
human polymorphonuclear cells and monocytes.335 PVL is a bicomponent toxin that consists of the 
polypeptides lukS-PV and lukF-PV.336 It releases proinﬂ ammatory mediators and vasodilatating 
factors that induce severe inﬂ ammatory lesions,337 and causes leukocyte destruction and tissue 
necrosis.209 PVL is detected in fewer than 5% of all S. aureus clinical isolates. It is especially found 
in  community-acquired MRSA but also in MSSA strains.338 it is mainly associated with necrotic 
lesions of skin and subcutaneous tissues, such as furuncles, and also with severe, necrotizing, 
community-acquired pneumonia.209,339 Although PVL-producing S. aureus affects healthy children 
and young adults the mortality rate of necrotizing pneumonia is nearly 75%.94,340
Staphylococcal enterotoxins, toxic shock syndrome toxin-1, and epidermolytic toxins display 
superantigenic properties.341,342 Superantigens cause endotoxin-like shock including endothelial 
leakage, hemodynamic shock, and multiorgan failure by releasing proinﬂ ammatory cytokines.86,319 
Staphylococcal superantigens may also be important virulence determinants in experimental 
septic arthritis.343
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2.7.2. Molecular typing and clonal spread of Staphylococcus aureus  
Typing of S. aureus is mainly indicated in hospital outbreaks and for characterization of methicillin-
resistant strains. During the last decades, traditional methods of S. aureus strain typing, such 
as serotyping and bacteriophage typing, have been supplemented and replaced with newer 
molecular methods including plasmid ﬁ ngerprinting, ribotyping, PCR-based methods, sequencing 
and pulsed-ﬁ eld gel electrophoresis (PFGE).323,344 Bacteriophage typing can still, in some cases, 
be considered for epidemiologic studies when a large collection of S. aureus strains from different 
geographical areas and laboratories is to be typed.344 At present, the golden standard typing 
method for S. aureus is PFGE, where the staphylococcal genomic DNA is cleaved into large DNA 
pieces by the restriction enzyme Smal followed by pulsed gel electrophoresis in order to obtain 
sufﬁ cient separation of the DNA pieces.345 Furthermore, multilocus sequence typing (MLST) is 
based upon DNA sequencing of seven housekeeping genes and provides a method to identify 
clonality of MRSA or MSSA isolates.346 Resistance to methicillin is determined by the mecA 
gene, which is a part of an additional DNA region, the staphylococcal cassette chromosome mec 
(SCCmec).87 At least ﬁ ve SSCmec types have been identiﬁ ed (I-V).338,347 Types I-III are shown to 
belong to hospital clones, whereas types IV and V of SCCmec are associated with community-
acquired MRSA infections.86 
Molecular typing techniques have not only allowed the identiﬁ cation of pandemic clones of 
MRSA, but have also enabled the monitoring of MRSA clones circulating in different hospitals 
and at different time intervals.348 Five major MRSA clones (i.e., Iberian, Brazilian, Hungarian, 
New York-Japan and Paediatric pandemic clones) account for almost 70% of isolates that have 
spread in recent years across the continents.348 Cross infections and epidemic spread of a 
single S. aureus (including MRSA) clone in addicts have been reported in Europe and North 
America.182,349,350 
In Finland, the majority of clinical MSSA isolates (from all infection sites) share genotypes 
with non-multiresistant MRSA, including community-acquired MRSA.87 In agreement with 
another recent Finnish report,351 dissemination of MRSA is not entirely due to clonal spread 
of multiresistant pandemic clones. Instead, several prevalent clones of MSSA seem to have 
acquired the SCCmec. Epidemic MRSA strains FIN-16 and FIN-21 are shown to be associated 
most frequently with MRSA bacteremias in Finland.352 Furthermore, FIN-4, FIN-11 and FIN-14 
strains have been related to community-acquired MRSA infections.353
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The highly virulent community-acquired MRSA strain USA400 (prototype strain, MW2) with PVL 
production has been observed to cause fatal septicaemia and septic arthritis among healthy 
children and young adults in the United States.354,355 It is unclear whether MSSA clones have 
a particular ability to cause serious infections. In a recent study, MSSA clones with sequence 
types (ST) 1, 25, and 30 were associated with community-acquired invasive disease, which may 
indicate virulence of these clones.346 
2.7.3. Serological diagnostic assays
Teichoic acid antibody
During the past 30 years numerous serological tests have been introduced to distinguish between 
patients with uncomplicated or complicated SAB. The teichoic acid antibody (TAA) assay is 
the most thoroughly investigated serological test and probably also the most frequently used. 
A TAA titer of 1:8 or more is considered clearly positive in patients with SAB, especially in 
endocarditis.69,356 A titer of 1:2 or 1:4 should be regarded as suggestive for a S. aureus infection 
although cross-reactions with other bacteria have been reported.357 In addition, a generally 
acceptable sign of active S. aureus disease is a fourfold rise in TAA titer.356 A TAA response is 
expected to develop during the ﬁ rst 14 to 28 days of infection.358,359 However, almost one third of 
patients may not have detectable antibodies on admission to hospital. 
During the 1970s and 1980s several studies on TAA determined by gel diffusion and counter-
immunoelectrophoresis were published, until the more sensitive and speciﬁ c gel diffusion assay 
(Endo-Staph) became available.360 Results from the different studies have shown extreme 
variability due alterations of standardization.360,361 For example, patients with complicated SAB 
had a positive TAA response in between 23% to 100%,318,358,362-364 while in some studies even 44% 
of healthy control sera were positive.363 Several possible explanations for the divergent results 
of serologic studies have been proposed: (1) variation of antigen preparation; (2) differences 
in methods used; (3) variation in the cut-off points for positive serological response; (4) limited 
patient material; (5) varying criteria for selecting patients; (6) and lack of accurate deﬁ nitions for 
the endocarditis.360,365 The highest sensitivity for elevated TAA values has been seen in patients 
with S. aureus endocarditis, especially among IDUs.356,357,359,366-368 This serological response in 
IDUs is most probably due to previous and recurrent intravenous exposure to S. aureus.362,368 
Furthermore, use of TAA assay may be useful particularly in chronic S. aureus infections.369 
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Antibody against staphylolysin (α-haemolysin)
The ﬁ rst test available for routine use was the antistaphylolysin (ASTA) assay. A titer of ≥2.0 IU/ml 
in it has been regarded as positive.370 The diagnostic value of ASTA is considered limited due 
to its low sensitivity.356 This has been shown in some studies, where the serological response 
was observed in only 32% to 62% of patients with complicated SAB or endocarditis.371,372 ASTA 
has been extensively studied in dermatological patients where ASTA values have correlated to 
the barrier function of the skin rather than to the actual stage of infection.373 High ASTA titers 
have been found in patients with various dermatoses, especially those with atopic dermatitis and 
chronic pruritic dermatoses.373,374 Comparisons of TAA and ASTA have shown correlation between 
antibodies against these two antigens with TAA being positive earlier than the ASTA.356,375 
However, no single serologic assay has proven to be positive in all patients with SAB or to be 
able to differentiate between patients with uncomplicated or complicated bacteremia.360 
Combined serological tests
Various S. aureus antigen preparations including whole S. aureus cells, peptidoglycan, teichoic 
acid, α-haemolysin, an ultrasonicate of S. aureus cells and lipase have been used.365,369 The 
combined use of these various serological tests may increase their positive predictive value.320 
However, according to recently published data none of the assay combinations have become 
valuable diagnostic aids in SAB or endocarditis.365 In addition, antibody levels against teichoic 
acid, α-haemolysin and lipase were even lower in patients with complicated SAB as compared 
to those with uncomplicated SAB in one study.376 The need for serological tests to assist in the 
diagnosis of S. aureus infections has changed in favour of other techniques such as computed 
tomography, isotope scanning, echocardiocraphy, and magnetic resonance.320
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3. AIMS OF THE STUDY
The purpose of the present study was to evaluate the epidemiology, incidence, clinical 
manifestations, treatment, outcome, strain characteristics and their virulence factors, and host 
immune responses among patients with SAB in a country with low prevalence of methicillin 
resistance.
The speciﬁ c aims were: 
I  To evaluate trends in the incidence, outcome and morbidity of SAB in Finland during 
1995-2001 and to assess the proportion of nosocomial versus community-acquired SAB. 
II To ﬁ nd out if levoﬂ oxacin combined with the currently used antibiotic treatment of SAB 
would improve the patient outcome as reduced mortality or complications such as deep 
infections. 
III To compare risk factors, site of valvular involvement, clinical manifestations, and outcome 
of S. aureus endocarditis among IDUs and nonaddicts.
IV To compare patient characteristics, the bacterial strains and their virulence factors, and 
host immune responses in order to explain the different prognosis and risk of developing 
endocarditis among IDUs and nonaddicts. 
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4. MATERIALS AND METHODS
4.1. Patients
Study I was based on a retrospective laboratory-based surveillance data on S. aureus bacteremia 
(SAB) in Finland. From January 1995 to December 2001, at least one isolation of S. aureus from 
blood was informed by 30 clinical microbiology laboratories to the National Infectious Disease 
Register (NIDR). Each notiﬁ cation included the following information: date of specimen, patient`s 
date of birth, patient`s sex and treating healthcare facility. Using this information and a time 
interval of three months, multiple episodes of the same case were merged into one case, either 
by the notifying laboratory or in the NIDR database (n = 5690 notiﬁ cations). A case was deﬁ ned 
as a person with SAB identiﬁ ed through the NIDR from 1995 to 2001. National identity codes 
for each person with SAB were collected retrospectively from the primary diagnostic laboratory, 
either in electronic format or on paper. After the collection of the national identity codes from each 
notiﬁ ed patient, and after exclusion of recurrent episodes, a total of 5045 cases were identiﬁ ed. 
Studies II-IV comprised of a prospective, randomized, multicenter trial conducted in ﬁ ve university 
hospitals and seven tertiary care hospitals in Finland. Adult patients with at least one blood 
culture positive for methicillin-sensitive S. aureus (MSSA) were included within 1-7 days of blood 
culture sampling. The ﬁ rst part of the study included patients from January 1999 to May 1999 
(designated as FINTROVA) but was interrupted due to withdrawal of the study drug, trovaﬂ oxacin, 
from the market. The study was continued using levoﬂ oxacin with the same patient group from 
January 2000 to August 2002 (designated as FINLEVO). Patients with SAB were randomly 
assigned to receive either standard treatment or standard treatment combined with trovaﬂ oxacin 
(FINTROVA) or levoﬂ oxacin (FINLEVO). Randomization was done blindly and separately at each 
study location after the patient or his/her representative had given written informed consent. 
However, seriously ill patients, for example unconscious patients with assisted ventilation, could 
be taken into the study without signed informed consent, because they were assumed to beneﬁ t 
most from the study medication. As soon as possible, a signed informed consent was taken 
from the patient or his/her representative. After randomization the treatments were open for the 
investigator and the patient. 
Exclusion criteria included age younger than 18 years, imprisonment, proven or suspected 
pregnancy, breastfeeding, epilepsy, another bacteremia during the previous 28 days, polymicrobial 
- 44 -
bacteremia (≥3 microbes), history of allergy to any quinolone antibiotic, previous tendinitis during 
ﬂ uoroquinolone therapy, prior ﬂ uoroquinolone use for more than ﬁ ve days before randomization, 
positive culture for S. aureus only from a central intravenous catheter, neutropenia (<0.5 x 
109/L), failure to supply an informed consent or glucose-6-phosphate dehydrogenase deﬁ ciency 
(FINTROVA only). Patients with bacteremia due to MRSA and a S. aureus strain resistant to any 
ﬂ uoroquinolone and those with meningitis at the time of randomization were also excluded. In 
total, 430 patients were randomized into both trials (49 patients into FINTROVA and 381 into 
FINLEVO). 
4.2. Study designs 
Study I was a retrospective epidemiological population-based study, in which the trends in the 
age- and sex-speciﬁ c annual incidence, proportion of nosocomial versus community-acquired 
bacteremia, and outcome of SAB during 1995-2001 were evaluated. Preceding hospitalizations 
for all study patients with SAB were obtained from the national hospital discharge registry 
(HILMO), which included records on patient`s identity information, admission and discharge 
dates, healthcare provider, type of service, specialty, patient`s place of residence (home or 
institution) at the time of presentation to the institution, and data on surgical procedures. The 
outcome (case fatality rate) at seven days and 28 days, and at three months after the date 
of the ﬁ rst S. aureus-positive specimen for a particular patient was obtained from the national 
population registry, using the national identity codes. 
Study II was a prospective trial, in which 1226 patients with SAB were identiﬁ ed during the 
FINLEVO study period (Fig. 4). In total, 381 patients were included in the analysis, with 191 
patients in the levoﬂ oxacin and 190 patients in the standard treatment group. All patients were 
followed up by an infectious disease specialist during the hospital treatment and thereafter with 
control visits at 28 days and at three months. Primary end-points were case fatality rate at 28 days 
and at three months. Secondary outcome measures included the number of complications (e.g., 
deep infections) observed after the ﬁ rst week of antibiotic treatment, decrease in serum C-reactive 
protein (CRP) concentration, length of antibiotic treatment, need for surgical intervention, and 
time to defervescence. Laboratory tests were conducted on the day of positive blood culture for 
S. aureus, at randomization and every other day during the ﬁ rst week, twice a week thereafter 
during hospitalization, at 28 days, and at three months. 
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Figure 4. Patients with Staphylococcus aureus bacteremia in the study sites for FINLEVO and 
number of patients incluced into analyses. *Excluded patients consisted of 100 patients with 
failure to supply an informed consent or patient refusal, 48 with neutropenia (<0.5 x 109/L), 42 
deaths prior to randomization, 30 with epilepsy or prior convulsion, 23 with prior ﬂ uoroquinolone 
use for more than 5 days preceding randomization, 15 with a ﬂ uoroquinolone resistant strain of S. 
aureus, 15 with meningitis, 13 with polymicrobial bacteremia (≥3 microbes), eight with a positive 
culture for S. aureus only from a central intravenous catheter, seven with another bacteremia 
during the previous 28 days, ﬁ ve with bacteremia due to methicillin-resistant S. aureus, three 
with proven or suspected pregnancy, two prisoners, two breastfeeding women, one with a history 
of allergy to quinolone, one with bacteremia caused by borderline oxacillin-resistant S. aureus. 
Additionally, 530 patients with SAB were identiﬁ ed during the study period but not evaluated for 
the trial.
1226 patients with
Staphylococcus aureus bacteremia
846 patients
excluded or not evaluated*
381 randomized in
intention-to-treat analysis
191 in levofloxacin
group
190 in standard
treatment group
19 patients excluded
(levofloxacin <2 wk)
11 patients excluded
(any fluoroquinolone ≥1 wk)
351 patients in
per-protocol analysis
172 in levofloxacin
group
179 in standard
treatment group
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Study III comprised all patients with endocarditis from the original FINTROVA and FINLEVO 
trials of 430 patients with SAB. Deﬁ nite or possible endocarditis as deﬁ ned by the modiﬁ ed Duke 
criteria75 was found in 74 patients, of whom 20 were IDUs and 54 were nonaddicts. Transthoracic 
echocardiography (TTE) and/or transesophageal echocardiography (TEE) was performed as 
clinically indicated by experienced echocardiographers. Two-dimensional imaging from multiple 
tomographic planes and spectral Doppler and colour ﬂ ow imaging were used in all study sites. 
The presence of cardiac vegetations, oscillation, paravalvular or intracardiac abscess, new 
valvular regurgitation, prosthetic valve dehiscence, and valve perforation were recorded.75 Case 
fatality rates were obtained at seven days and 28 days, and at three months. Other clinical 
outcome measures were the site of valvular involvement, evidence of extracardiac deep infections 
or thromboembolic events, need for cardiac surgery, and duration of fever and hospitalization. 
Study IV comprised all patients with identiﬁ able IDUs and an equal number of controls from 
the original FINTROVA and FINLEVO trials of 430 patients with SAB. In total, 44 IDUs were 
identiﬁ ed and 20 of them had endocarditis (19 deﬁ nite according to modiﬁ ed Duke criteria).75 
To study differences in clinical characteristics, bacterial strains and host serological responses 
between IDUs and nonaddicts, a control patient for each addict was chosen. For each case with 
endocarditis (n=20), we chose a control with preferably deﬁ nite endocarditis and obtaining a 
convalescent serum sample at 28 days. Thus, controls with endocarditis consisted of 16 deﬁ nite 
and four possible endocarditis. For each case without endocarditis (n=24), we chose an age (±15 
years) and sex matched control whose randomization time was the nearest possible. The site 
of valvular involvement, evidence of deep infections or thromboembolic events, and duration of 
fever and hospitalization were detected within three months follow-up. S. aureus isolates were 
genotyped by pulsed-ﬁ eld gel electrophoresis (PFGE), and tested for Panton-Valentine leukocidin 
(PVL), staphylokinase (SAK), protease and haemolysin production. Acute and convalescent sera 
were tested for antibodies against α-haemolysin (ASTA) and teichoic acid (TAA). Information on 
drug injection history, drug-use practices, and drugs were available only from 29 IDUs.
4.3. Deﬁ nitions
In Study I, SAB was deﬁ ned as nosocomial if the ﬁ rst positive blood culture was obtained 
two days or more after hospital admission or if obtained within two days of admission with a 
preceding hospital discharge within seven days. SAB was classiﬁ ed as community-acquired if 
the specimen positive for the blood culture was obtained within two days of admission and there 
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were no hospitalizations within the preceding seven days. The origin of SAB was deﬁ ned as 
unknown if no periods of hospitalization could be identiﬁ ed for a patient.
In studies II-IV, SAB was hospital-acquired if the ﬁ rst positive blood culture was obtained ≥48 
hours after admission, or the patient was a resident in a long-term care facility or attended 
hemodialysis within the preceding two months. All other cases were deﬁ ned as community-
acquired. Prognosis or severity of underlying diseases were divided as healthy, nonfatal, 
ultimately, or rapidly fatal according to the criteria of McCabe and Jackson.377 The infection focus 
was classiﬁ ed as deﬁ nite if it was documented by bacteriological, radiological or pathological 
investigations, but suspected if it was evident from clinical ﬁ ndings only. Infection of a central 
intravenous catheter was deﬁ ned by the guidelines of the Infectious Diseases Society of 
America.133 Endocarditis was classiﬁ ed as deﬁ nite or possible using the modiﬁ ed Duke criteria 
by clinical, pathological, and echocardiographic data.75 Deep infection was characterized as 
endocarditis, pneumonia, deep-seated abscess, osteomyelitis, septic arthritis, meningitis, septic 
thrombophlebitis, mediastinitis, urinary tract infection, infection of any prosthetic device or 
recurrent SAB. Relapse of SAB was conﬁ rmed by the same resistance pattern and PFGE typing 
for two S. aureus strains. Other recurrences of S. aureus culture in the blood were classiﬁ ed as 
reinfections. CRP was deﬁ ned as normal when less than 10 mg/L. Leukocytosis was determined 
if white blood cell count was over 12 x 109/L and leukopenia when white blood cell count was less 
than 4 x 109/L. Thrombocytopenia was deﬁ ned as a blood platelet count less than 100 x 109/L, 
and acidosis with venous blood pH <7.30. Elevated liver enzymes were deﬁ ned as an increase of 
alanine aminotransferase (ALT) >120 U/L in females and >150 U/L in males, alkaline phospatase 
>300 U/L or bilirubin >40 µmol/l. Time to defervescence was recorded in days until the axillary 
temperature was <37.5oC.
In studies III-IV, IDUs were deﬁ ned as patients who had injected drugs within the past six 
months before randomization. Severe sepsis at the time of the ﬁ rst blood culture positive for 
S. aureus was classiﬁ ed as an infectious process leading to organ dysfunction or signs of 
hypoperfusion or hypotension.378 Furthermore, endocarditis of a prosthetic valve was deﬁ ned 
as early when occurring ≤60 days after valve replacement and as late >60 days after valve 
replacement. Arterial thromboembolic events comprised acute myocardial infarction or unstable 
angina, parenchymal and cerebral embolization or infarction, and mycotic aneurysm. Venous 
thromboembolic manifestations were deﬁ ned as septic or venous pulmonary embolism, and 
deep venous thrombosis. 
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4.4. Study treatments
Studies II-IV consisted of patients with SAB who were randomly assigned to receive either 
standard treatment or it combined with a ﬂ uoroquinolone (trovaﬂ oxacin or levoﬂ oxacin). However, 
Study II presents only the effect of levoﬂ oxacin combination therapy on patient outcome. The 
results of trovaﬂ oxacin efﬁ cacy in combination therapy have not been analyzed or published.
The study protocol for antibiotic treatment in Study II is summarized in Table 1. Primarily, the 
standard treatment consisted of an intravenous semisynthetic penicillin, cloxacillin or dicloxacillin 
(2 g q4h). Alternatively, cefuroxime (1.5 g q6h), clindamycin (600 mg q6-8h), or vancomycin 
(1 g bid) were allowed if a contraindication for the use of penicillins was noted. However, 
clindamycin was not recommended in endocarditis. When oral treatment was indicated, cloxacillin 
(500 mg q6h), cephalexin or cefadroxil (500 mg q6h), or clindamycin (300 mg q6h) were 
accepted as standard therapy. In cases of renal dysfunction the antibiotic doses were adjusted 
as recommended by the manufacturers. In the ﬂ uoroquinolone treatment group, the dose of 
levoﬂ oxacin both intravenously and orally was 500 mg once daily for patients under 60 kg and 
500 mg bid for those over 60 kg in weight. If endocarditis was clinically suspected or conﬁ rmed, 
an aminoglycoside (either tobramycin or netilmicin at 1 mg per kilogram of body weight q8h) 
was added to the drug therapy described above. Rifampicin (450 mg once daily for patients 
under 50 kg and 600 mg once daily for patients over 50 kg in weight, orally or intravenously) 
was given if there was a suspicion or evidence of endocarditis, or other deep infections. Any 
antibiotic treatment was avoided or discontinued if 1) a contraindication (e.g., renal failure and an 
aminoglycoside), 2) a serious adverse event such as an allergic reaction, or 3) a drug interaction 
occurred or could be expected (e.g., problematic warfarin therapy during rifampicin).
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Table 1. Study protocol for antibiotic therapy in patients with Staphylococcus aureus bacteremia 
 randomized either standard treatment or combined with levoﬂ oxacin.
aAlternatively dicloxacillin.
bIncludes both right-sided and left-sided endocarditis, and native and prosthetic valve involvement.
The duration of antibiotic treatment was determined by the treating physician. However, all 
patients received at least 14 days of intravenous antibiotic treatment. In SAB associated with a 
central intravenous catheter the antibiotic treatment was discontinued after 14 days when the 
catheter was removed, and there were no evidence of endocarditis or other deep infections 
(Table 2).133 When endocarditis or other deep infection was veriﬁ ed or clinically suspected, 
intravenous standard antibiotic and rifampicin were recommended to be continued for at least 
four to six weeks. In endocarditis, aminoglycoside was completed after seven days.22,28 In the 
ﬂ uoroquinolone treatment group, patients received levoﬂ oxacin for at least for four weeks of 
which the drug was given intravenously at least for the ﬁ rst 14 days. 
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Table 2. Duration of the standard antibiotic treatment in different subgroups of Staphylococcus 
 aureus bacteremia. 
aAlternatively dicloxacillin.
4.5. Microbiological methods
Blood was cultured using the BacT Alert System (Organon-Teknika, Boxtel, The Netherlands) 
in seven hospitals and the Bactec system (BD Diagnostic Systems, Sparks, Md, United States) 
in ﬁ ve hospitals. Aliquots of bottles with a positive signal were Gram stained and subcultured 
on chocolate agar plates. S. aureus isolates were identiﬁ ed by standard laboratory methods 
including colony morphology, Gram staining, production of DNAase and urease as well as ability 
to use mannitol and trehalose. Antimicrobial drug susceptibility was tested by the disk diffusion 
method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). 
The antibiotics tested included oxacillin, cephalexin, clindamycin, erythromycin, levoﬂ oxacin, 
trovaﬂ oxacin, fucidic acid, rifampicin, trimethoprim-sulfamethoxazole, and vancomycin. MICs of 
oxacillin were determined by E-test (AB Biodisk, Solna, Sweden) according to the manufacturer`s 
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instructions. The interpretative criteria for the zone diameters of growth inhibition were according 
to the CLSI with the following equivalent MIC breakpoints for levoﬂ oxacin: susceptible, ≤2 ug/mL; 
resistant, ≥8 ug/mL. For rifampicin, the used corresponding CLSI breakpoints were: susceptible, 
≤1 ug/mL; resistant, ≥4 ug/mL. 
In Study IV, PFGE was performed by using the Harmony protocol379 where the genomic DNA was 
digested with the restriction endonuclease SmaI (Boehring Mannheim, Mannheim, Germany) in 
agarose blocks prepared as described elsewhere.380 Chromosomal fragments were separated 
using a Chef DR III or Chef Mapper XA apparatus (Bio-Rad Laboratories, Hercules, CA). PFGE 
running conditions consisted of two blocks: block one with switching times of 5 s and 15 s and a 
running time of 10 h, and block two with switching times of 15 s and 60 s and a running time of 13 
h. PFGE proﬁ les were analyzed according to the following criteria: strains sharing identical band 
proﬁ le were considered the same, those differing 1-3 bands were interpreted as closely related, 
and those differing 4-6 bands were interpreted as possibly related. Strains differing for seven or 
more bands were considered to be unrelated.344 According to these rules, strains differing by less 
than seven bands from one another were ascribed the same type name. The S. aureus PFGE 
database at the National Public Health Institute was used as the basis for naming the strains. 
Proﬁ les that had been previously found among epidemic MRSA or MSSA strains were indicated 
by FIN- and MSSA-codes, respectively. A sporadic strain possessed a previously unknown PFGE 
proﬁ le.
Furthermore, in order to determine SAK production in Study IV, staphylococci were grown in 
Todd-Hewitt broth overnight at 37oC and centrifuged at 2700 x g for 10 min at room temperature. 
The clear culture supernatants were used for SAK determination as described.332 Strains were 
also tested for haemolysin and protease production by streaking two colonies of a strain on 
bacterial agarose plates containing either sheep red blood cells (1 mg/ml) or skimmed milk 
powder (w/v). The haemolytic and protease activities were determined visually as negative if 
they were weaker than the ones caused by the control organism, S. aureus strain Cowan I, and 
positive if the effects were equal or stronger than the control. The presence of PVL genes (lukS-
PV-lukF-PV) was detected by PCR.209 To conﬁ rm the functionality of the PVL-PCR reaction and 
the quality of the DNA, nuc gene was ampliﬁ ed at the same time.381 S. aureus strain CCUG 
46923 was used as a positive control for the PCR.
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4.6. Serological methods
In Study IV, serum samples were collected after the ﬁ rst positive blood culture for S. aureus at 
days two to seven (acute phase), and at days 22 to 28 (convalescent phase). After the samples 
had coagulated at room temperature, sera were collected by centrifugation and stored at -20oC 
for further analysis. Serum antibody titers against staphylolysin or staphylococcal α-haemolysin 
were measured as described by Larinkari with minor modiﬁ cations.373 Two-fold dilutions of heat 
inactivated (30 min at 56oC) patient sera, antistaphylolysin standard (Dade Behring Marburg 
GmbH, Marburg, Germany), and control sera were incubated with a determined amount of 
staphylolysin (Dade Behring) for 15 min at 37oC and, after addition of washed rabbit red blood 
cells, for an additional 45 min. After incubation, the red cells were mixed with a horizontal rotatory 
shaker, pelleted by centrifugation and ﬁ nally incubated at room temperature for 3 h. Finally, 
the threshold for inhibition of haemolysis was determined as the ﬁ rst dilution where a yellowish 
colour was detectable around pelleted red blood cells. A single value ≥3.2 IU/ml, and a 4-fold or 
greater rise in titers were regarded as positive. 
Antibody titers against staphylococcal ribitol teichoic acid were determined by a gel double 
diffusion assay according to manufacturer`s instructions (Endo-StaphR, Meridian Bioscience Inc., 
Cincinnati, Ohio, USA). A single value ≥8, and a 4-fold or greater rise in titers were regarded 
as positive. The limits of ASTA and TAA titers represent 98-99th percentile values in the healthy 
Finnish population during the study period.
4.7. Statistical methods
4.7.1. Incidence rates
In Study I, annual data from the national population registry from years 1995-2001 were used 
as denominators to calculate age- and sex-speciﬁ c incidence rates as well as the blood culture 
sampling rates. The average annual incidences during the surveillance period were calculated 
by using the total number of cases and population during 1995-2001. To evaluate secular trends, 
rates of SAB in different age and sex groups were calculated for each 12-month period from 
January 1995 to December 2001. Poisson regression with the PROC GENMOD procedure was 
used to assess whether the observed changes in the rates were statistically signiﬁ cant. Pearson 
correlation coefﬁ cients (and p values) were calculated over seven years for the relationship 
between the incidences of SAB and rates of blood-cultures processed. 
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4.7.2. Sample size and patient populations
In the sample size calculation, when mortality was assumed to be 10% in the levoﬂ oxacin group 
and 20% in the standard treatment group, a power of 80% would be achieved with 198 patients 
in each study arm (Study II). A two-tailed signiﬁ cance level of 5% was used. Data were analyzed 
from three different patient populations, primarily by intention-to-treat (ITT) analysis with 381 
patients (Fig. 4). Secondary analysis was performed by per-protocol (PP) (351 patients). Patients 
were ineligible for PP analysis if they had received levoﬂ oxacin <2 weeks in the levoﬂ oxacin 
group, or any ﬂ uoroquinolone for ≥1 week within the ﬁ rst 28 days after randomization in the 
standard treatment group. All collected data except demographic characteristics were analyzed 
in both ITT and PP populations, but only results from ITT analyses are shown. Additionally, the 
length of antibiotic therapy was analyzed from a population of which deceased patients were 
excluded (308 patients). 
4.7.3. Statistical analysis
Statistical analyses were performed with Epi Info software, version 6.04 (Centers for Disease
Control and Prevention, Atlanta, GA, USA) (Study I), SAS® version 8.2 (Study II), and SPSS 
version 12.0 (SPSS Inc., Chicago, IL, USA) (Studies I, III and IV). The primary variable and other 
categorical variables were analyzed by the chi-squared test or Fisher`s exact test, as appropriate. 
Continuous baseline variables were compared using the t-test or the Mann-Whitney test. Odds 
ratios (OR) with 95% conﬁ dence intervals (CI) were calculated to estimate the signiﬁ cance of 
differences in patient groups. 
In Study II, the stratiﬁ ed Cochran-Mantel-Haenszel (CMH) test was used in order to adjust for 
levoﬂ oxacin as a confounding factor when the effect of rifampicin was analyzed, and to adjust 
for other variables, including age, nosocomial acquisition, McCabe`s classiﬁ cation, endocarditis, 
and the number of deep infections to compare mortality between patients with or without 
rifampicin treatment. The results of variables described above have not been published before. 
Additionally, a decrease in serum CRP concentration was analyzed using Analysis of Variance for 
Repeated measurements (RMANOVA). Mortality and time to defervescence survival estimates 
were calculated with the Kaplan-Meier method. The log-rank test (Study II) and Cox regression 
analysis (Study III) were used to compare the survival estimates. Survival was calculated from 
the day of randomization (Study II) and from the day of the ﬁ rst positive blood culture (Study III) 
until three months. All tests were two-tailed, and p <0.05 was considered to be signiﬁ cant. 
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4.8. Ethical aspects
Appropriate permissions were acquired from the Ministry of Social Affairs and Health, the Finnish 
data protection authority, and the National Research and Development Center for Welfare and 
Health to use the data from the national hospital discharge registry and the national population 
registry (Study I). FINTROVA and FINLEVO trials were approved by the ethics committees of all 
study sites and by the Finnish National Agency for Medicines (Studies II-IV). The patients or their 
representative gave a written informed consent. From seriously ill patients consent was taken as 
explained before (section 4.1.).
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5. RESULTS
5.1. Trends and outcome of Staphylococcus aureus bacteremia in Finland 
 during 1995-2001 (Study I)
5.1.1. Proportion and incidence of SAB according to hospital- and community-acquired
          cases, age, sex, and region 
During the study period, 2546 of 5045 (51%) SAB cases were classiﬁ ed as hospital-acquired 
and 2203 (44%) cases as community-onset, while 296 (6%) were of unknown origin. Among the 
2546 nosocomial SAB, the positive blood culture was obtained >2 days after hospital admission 
in 1794 (70%) cases and within two days in 752 (30%) cases. The proportion of nosocomial 
SAB was 51% in both 1995 and 2001 without any change during the observation period (range 
48%-53% by year and 44-57% by region) (Table 3).
The median age of the patients was 62 years (range, 0-100) and 3041 (60%) were males. Female 
patients were signiﬁ cantly older than male patients (median age, 68 vs. 59 years; p <0.001), 
and the patients with nosocomial infection were signiﬁ cantly older than those with community-
acquired infection (median age, 66 vs. 59 years; p <0.001). The incidence rates of SAB varied 
substantially by age and sex (Table 4) and were highest at the extremes of the life span. In all 
age groups, the incidence rates were at least 1.5 times higher in males than in females. The 
difference was most pronounced (i.e., 2.4-2.5 times higher) in the age groups between 35 and 
64 years. In adult age groups, the rates consistently increased by age in both genders, beginning 
in males at clearly a younger age group than in females. The proportion of nosocomial SAB was 
highest in infants and elderly persons and was slightly higher in female than in males in age 
groups between 15 and 34 years. 
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Table 3. Incidence of Staphylococcus aureus bacteremia according to region and year, 
 and proportion of hospital-onset infections, Finland, 1995-2001. 
    SAB, Staphylococcus aureus bacteremia.
      aAverage annual incidence (cases per 100,000 population).
Table 4. Incidence of Staphylococcus aureus bacteremia by age group and sex, 
 Finland, 1995-2001. 
 
      aAverage annual incidence (cases per 100,000 population).
The average annual incidence of SAB was 14 cases per 100,000 population. The annual 
incidence of SAB rose by 55%, from 11 per 100,000 population in 1995 to 17 per 100,000 
population in 2001 (p <0.001). The incidence of disease varied by region, being maximally from 
14 cases to 22 per 100,000 population in 2001 (in Tampere and Kuopio, respectively) (Table 
3). The increase in incidence was detected in both genders, although it was slightly greater in 
females (63%, from 8 per 100,000 population to 13) than in males (40%, from 15 per 100,000 
population to 21). The increase occurred only in adults and was signiﬁ cant in all adult age groups 
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(p values from 0.012 to <0.001), except in the range of 55-64 years of age. The increase was 
most distinct in persons >74 years of age, in whom it rose from 36 per 100,000 population in 
1995 to 63 per 100,000 population in 2001 (Fig. 5). 
Figure 5. Annual incidence of Staphylococcus aureus bacteremia by age group, 
 Finland, 1995-2001.
During the study period, a total of 1,128,321 blood culture sets were processed in 30 Finnish 
microbiology laboratories. The rate of blood culture sampling rose by 21%, from 28 blood-culture 
sets per 1000 population in 1995 to 35 in 2001 (range of increase by region, 9-27%), associated 
signiﬁ cantly with increasing incidence of SAB detected during 1995-2001 (p <0.001). 
5.1.2. Outcome
Among the 5045 patients with SAB, 465 (9%) died within seven days after the ﬁ rst blood culture 
positive for S. aureus, 875 (17%) died within 28 days, and 1217 (24%) within three months. The 
median age of persons who died within 28 days was signiﬁ cantly higher than that of those who 
survived (73 vs. 59 years; p <0.001). The case fatality rate increased with age, being lowest 
in the age group 1-14 years and highest in the group >74 years of age (Article I: Table 2). 
The case fatality rates at seven and 28 days, and at three months were signiﬁ cantly higher 
among nosocomial cases than among community-acquired cases (for all time frames; p <0.001). 
The annual rate of mortality within three months increased by 64% during 1995-2001, from 2.6 
deaths to 4.2 per 100,000 population per year. 
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5.2. Combination therapy with levoﬂ oxacin in Staphylococcus aureus  
 bacteremia (Study II)
5.2.1. Patient characteristics
Patients in the levoﬂ oxacin group and in the standard treatment group were well matched with 
respect to demographic characteristics and predisposing conditions (Article II: Table 1). When 
the underlying diseases were grouped by the predicted prognoses by McCabe`s classiﬁ cation,377 
61% of patients had a nonfatal, 27% had an ultimately fatal, and 3% had a rapidly fatal disease. 
Only 9% of the patients were previously healthy. In both groups the median time from sampling 
of the ﬁ rst positive blood culture to randomization was three days.
5.2.2. Antibiotic treatment
All patients were treated with an antibiotic that was effective against S. aureus from the time of 
the ﬁ rst positive blood culture. In ITT analysis, parenteral cloxacillin or dicloxacillin was given 
to 150 of 191 (79%) patients in the levoﬂ oxacin group and to 135 of 190 (71%) patients in 
the standard treatment group (p = 0.09). Only 31 (16%) patients in the levoﬂ oxacin group and 
42 (22%) patients in the standard treatment group were initially treated with cefuroxime with 
no signiﬁ cant difference between the groups (p = 0.15). The treatment groups differed neither 
in the use of clindamycin or vancomycin. Rifampicin was given more frequently to patients in 
the standard treatment group than in levoﬂ oxacin group (77% vs. 65%, respectively; p = 0.01). 
Combination therapy with an aminoglycoside was also signiﬁ cantly more common in the standard 
treatment group compared with the levoﬂ oxacin group (23% vs. 11%, respectively; p <0.001). 
The median duration of parenteral antibiotic therapy from randomization was 29 days (interquartile 
range [IQR], 22-36 days) in both groups (p = 0.76). Levoﬂ oxacin was given for a median of 42 
days (IQR, 28-58 days). Total duration of antibiotic therapy, including intravenous and oral dosing, 
was for a median of 72 days (IQR, 45-85 days) in the levoﬂ oxacin group and 80 days (IQR, 42-84 
days) in the standard treatment group (p = 0.90). 
5.2.3. Clinical manifestations 
A skin or soft tissue infection was found in 254 of 381 (67%) patients and no difference was 
observed between the treatment groups (Table 5). At least one deep infection was detected in 
331 of 381 (87%) patients during the three months follow-up. Deep infections were deﬁ nite in 
252 (76%) patients and suspected in 79 (24%) patients. Most of these (84%) were diagnosed 
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within one week after randomization (Table 5). A new deep infection after the ﬁ rst week was 
found equally often in the levoﬂ oxacin group and in the standard treatment group (17% vs. 16%, 
respectively; p = 0.80). The only signiﬁ cant difference in ITT analysis was the lower number 
of deep-seated abscesses in the levoﬂ oxacin group as compared to in the standard treatment 
group (2% vs. 7%, respectively; p = 0.02). However, this statistical difference was not detected 
in PP analysis. During follow-up, ﬁ ve (1%) patients had a new SAB more than 28 days after 
randomization with no signiﬁ cant difference between the groups. Recurrent SAB was due to a 
relapse in three patients and reinfection in two patients. The infection focus was treated with 
drainage or surgery in 224 of 381 (59%) patients with no signiﬁ cant difference between the 
groups. 
5.2.4. Outcome
No signiﬁ cant differences in mortality were observed between the treatment groups in ITT or in 
PP analyses in various subgroups (Table 6). The case fatality rate at 28 days was 14% in both 
study arms and at three months 21% in the standard treatment group and 18% in the levoﬂ oxacin 
group (ITT analysis).
The mean duration of fever (>37.5oC) was nine days in both groups (Article II: Figure 2). A 
decrease in the rate of serum CRP concentrations were similar in both groups (Article II: Figure 
2). No signiﬁ cant differences were observed between the treatment groups in the number of 
patients with leukocytosis, leukopenia, thrombocytopenia, acidosis, or liver enzyme elevations 
(data not shown). There were no signiﬁ cant differences in antibiotic-associated diarrhea caused 
by Clostridium difﬁ cile or allergic reactions between the treatment groups. 
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In a post hoc analysis, the case fatality rate at three months was observed to be signiﬁ cantly 
higher among those patients with a deep infection who did not receive rifampicin [25 (38%) of 
66 patients] than in patients treated with rifampicin [44 (17%) of 265 patients] (OR 3.06; 95% CI 
1.69-5.54; p <0.001) (Article II: Table 4). However, patients who did not receive rifampicin were 
signiﬁ cantly older and signiﬁ cantly more often had hospital-acquired SAB or a severe underlying 
disease than did those given rifampicin. In contrast, patients not treated with rifampicin had fewer 
deep infections per patient and fewer cases of endocarditis. Therefore, the effect of rifampicin 
on mortality was separately analyzed in these patient groups by univariate analysis (Table 7). 
Signiﬁ cantly lower mortality among patients treated with rifampicin as compared to those without 
it was observed in patients with nosocomial SAB, ultimately or rapidly fatal underlying disease, 
and those with more than two deep infections per patient (Table 7). However, rifampicin had no 
effect on mortality in patients with age >65 years or endocarditis in univariate analysis. When 
the effect of rifampicin was adjusted for these subroups (stratiﬁ ed CMH test) rifampicin had a 
statistically signiﬁ cant lowering effect on mortality in all these subgroups (Table 7). 
Table 7. Univariate and stratiﬁ ed analyses on mortality at three months in patients with deep 
 infection receiving combination therapy with or without rifampicin. 
CMH, Cochran-Mantel-Haenszel.
aChi-square test separately in subgroups for the effect of rifampicin on mortality. 
bChi-square test for the effect of rifampicin on mortality adjusted for subgroup variable. 
cPrognosis or severity of underlying diseases classiﬁ ed according to the criteria of McCabe and Jackson. 
dPossible or deﬁ nite endocarditis according to modiﬁ ed Duke criteria.
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Furthermore, rifampicin was found to be a confounding factor in the analysis for the effect 
of levoﬂ oxacin on mortality since rifampicin was added signiﬁ cantly more often to patients in 
the standard treatment group than in the levoﬂ oxacin group (p = 0.003) (Article II: Table 4). 
Therefore, the effect of levoﬂ oxacin on mortality in patients who had a deep infection was 
analyzed separately among those treated with or without rifampicin (stratiﬁ ed CMH test). The 
case fatality rate at three months among patients with deep infection and rifampicin treatment 
was 13% (15 of 119 patients) in the levoﬂ oxacin group and 20% (29 of 146 patients) in the 
standard treatment group. Case fatality rates in patients not treated with rifampicin were 37% 
(16 of 43 patients) and 39% (9 of 23 patients). The beneﬁ t of levoﬂ oxacin was not statistically 
signiﬁ cant in this stratiﬁ ed analysis either, in which the imbalance in the use of rifampicin was 
taken into account (p = 0.16). 
5.3. Clinical manifestations and outcome in Staphylococcus aureus 
 endocarditis (Study III) 
5.3.1. Patient characteristics among injection drug users and nonaddicts 
Endocarditis was observed in 74 of 430 (17%) patients with SAB. IE was detected in 20 of 
44 (46%) IDUs and in 54 of 386 (14%) nonaddicts (OR 5.12; 95% CI 2.65-9.91; p <0.001). 
Patients with endocarditis differed from those with SAB only by having signiﬁ cantly more often a 
predisposing heart disease or a pre-existing liver disease, but less preceding trauma (Article III: 
Table 1). Other predisposing characteristics and underlying diseases of the patients with IE did 
not differ from those with SAB. 
Among patients with endocarditis, IDUs as a group were younger and had less predisposing 
heart conditions, coronary artery disease or diabetes than nonaddicts (Article III: Table 2). When 
the underlying diseases were grouped by the predicted prognoses (McCabe`s classiﬁ cation),377 
none among the IDUs had a rapidly fatal or ultimately fatal disease but they were found in 20 of 
54 (37%) nonaddicts (p = 0.001). However, there were three IDUs with HIV infection. Only one 
drug abuser had a hospital-acquired bacteremia and none associated with the use of central 
intravenous catheter (Article III: Table 2). Severe sepsis was observed in 9 of 20 (45%) IDUs and 
in 28 of 54 (52%) nonaddicts without signiﬁ cant difference between the groups.
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5.3.2. Antibiotic treatment
Sixty-ﬁ ve of 74 (88%) patients were treated with cloxacillin or dicloxacillin with no signiﬁ cant 
difference between the groups. Seven (10%) patients received cefuroxime, and one received 
vancomycin and one ceftriaxone. The median duration of parenteral antibiotic therapy from the 
ﬁ rst blood culture positive for S. aureus was 30 days (IQR, 24-43 days) in IDUs, and 26 days 
(IQR, 13-34 days) in nonaddicts (p = 0.12), respectively. An aminoglycoside was more often 
given to addicts than to nonaddicts (95% vs. 54%, respectively; p = 0.001). Eighteen of 20 (90%) 
IDUs received rifampicin compared with 48 of 54 (89%) nonaddicts with no signiﬁ cant difference 
between the groups. 
5.3.3. Site of endocarditis and echocardiographic ﬁ ndings
According to the modiﬁ ed Duke criteria for endocarditis, 56 (76%) patients were conﬁ rmed as 
deﬁ nite (10 by pathologic criteria and 46 by clinical criteria), and 18 (24%) patients as possible 
(Table 8). Deﬁ nite endocarditis was more common among IDUs than in nonaddicts. Left-sided 
involvement was observed in 93% of nonaddicts whereas in 60% of cases among IDUs right-
sided endocarditis (tricuspid valve involvement in all patients) was detected. In nonaddicts, 
the aortic valve was slightly more often involved (44%) than mitral valve (35%). Prosthetic 
valve endocarditis, involving the left side only, occurred in 17 of 74 (23%) patients and they all 
presented in nonaddicts. Most of these patients had an early onset of prosthetic valve IE (12 
patients). 
Echocardiography was performed in 263 of 430 (61%) patients with SAB. Addicts underwent 
echocardiography more often (91%) compared with nonaddicts (58%) (OR 7.31; 95% CI 
2.56-20.84; p <0.001). In endocarditis, a vegetation was evident by echocardiography in 53% 
of cases, and a new regurgitation in 71% of cases without signiﬁ cant differences between the 
groups (Table 8). Only four patients had an intracardial abscess or valve perforation. 
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Table 8. Classiﬁ cation, valvular involvement and echocardiographic ﬁ ndings of injection drug 
 users and nonaddicts with Staphylococcus aureus endocarditis.
TTE, transthoracic echogardiography; TEE, transesophageal echogardiography.
aClassiﬁ ed according to modiﬁ ed Duke criteria.
bIncludes abnormal echocardiographic manifestations both in native valve or in prosthetic valve. 
cRepresents initial echocardiographic ﬁ ndings with TTE alone or with both TTE and TEE.
dRegurgitation observed on echocardiogram in any cardiac valve at the time of diagnosis of endocarditis.
5.3.4. Clinical manifestations and outcome
There were no differences in the clinical manifestations between the groups except the tendency 
for more frequent occurrence of various vascular phenomena among IDUs (Article III: Table 4). 
The most common infection focus was a skin or a soft tissue infection in 46 of 74 (62%) patients. 
An extracardiac deep infection was found in 85% of IDUs and in 89% of nonaddicts (p = 0.70). 
Two patients only developed recurrent bacteremia during the three months follow-up period. 
Vascular complications, including arterial or venous thromboembolic events, were detected in 
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60% of IDUs but in only 35% of nonaddicts (p = 0.07) (Article III: Table 4). In particular, septic 
pulmonary embolism was observed only in IDUs. Whereas all coronary artery related diseases 
were among nonaddicts, all three parenchymal embolic events were observed in drug abusers. 
Congestive heart failure in acute phase was present in 11 of 74 (15%) patients with no difference 
between the groups. 
Case fatality rate of all patients with endocarditis was 23% at 28 days, and 31% at three months 
(Table 9). Mortality was signiﬁ cantly higher in nonaddicts than in addicts both at 28 days (OR 
8.00; 95% CI 0.99-64.94; p = 0.03), and at three months (OR 5.73; 95% CI 1.20-27.25; p = 0.02). 
Signiﬁ cant factors for lower mortality in IDUs based on univariate analyses were injection drug 
abuse (HR 0.22; 95% CI 0.05-0.92; p = 0.04), age (HR 1.03; 95% CI 1.01-1.06; p = 0.006), and 
none or nonfatal underlying diseases by McCabe`s classiﬁ cation (HR 0.24; 95% CI 0.10-0.54; p 
= 0.001). Statistically signiﬁ cant association for mortality were not found with the following: right-
sided involvement (HR 0.30; 95% CI 0.07-1.30; p = 0.11), left-sided involvement (HR 2.31; 95% 
CI 0.69-7.78; p = 0.18), severe sepsis at the time of ﬁ rst positive blood culture for S. aureus (HR 
1.71; 95% CI 0.74-3.95; p = 0.21), or arterial embolic events (HR 2.15; 95% CI 0.94-4.90; p = 
0.07). After adjusting by age and underlying diseases, injection drug abuse was not any more 
signiﬁ cantly associated with lower mortality (HR 0.74; 95% CI 0.10-5.40; p = 0.77). 
There were no differences in median duration of fever (three days) or median duration of 
hospitalization (32 days) between IDUs and nonaddicts (Table 9). Cardiac surgery was performed 
in 15% of IDUs but only in 7% of nonaddicts (OR 2.21; 95% CI 0.45-10.87; p = 0.38). Leukocytosis 
at the time of ﬁ rst positive blood culture for S. aureus was more common in nonaddicts than in IDUs 
(55% vs. 15%, respectively; p = 0.003), and only two (4%) patients had leukopenia. The median 
of serum CRP concentration on the day of the ﬁ rst positive blood culture for S. aureus was 198 
mg/L in addicts compared with 171 mg/L in nonaddicts without a signiﬁ cant difference between the 
groups. Only two nonaddicts and none of IDUs had ALT level 2-fold above normal limit.
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Table 9. Outcome and surgical treatment of injection drug users and nonaddicts with 
 Staphylococcus aureus endocarditis.  
IQR, interquartile range.
aFever <37.5 oC after the ﬁ rst positive blood culture for S. aureus with 72 patients 
(two patients excluded, death before  defervescence).
bIncludes two patients with vegetectomy and one patient with annuloplasty.  
5.4. Host factors, microbiological and serological characteristics in 
 Staphylococcus aureus bacteremia and endocarditis among injection 
 drug users and nonaddicts (Study IV)
5.4.1. Patient characteristics 
Into Study IV, all 44 IDUs were included and group matched controls for them as described in the 
methods section 4.2. Matching was made separately for patients with and without endocarditis. 
Despite matching, IDUs as a group were signiﬁ cantly younger than nonaddicts (Table 10). In 
addition, IDUs had signiﬁ cantly more frequently community-acquired SAB, a pre-existing liver 
disease and HIV infection. In contrast, nonaddicts more often had ultimately or rapidly fatal 
diseases by McCabe`s classiﬁ cation.377 None of the 88 study patients had previous S. aureus 
deep infection, and prior SAB before the randomization was observed in 14% of IDUs as 
compared to 2% of nonaddicts (p = 0.11). 
Information on drug injection history, drug-use practices, and drugs were available from 29 IDUs. 
A high proportion of IDUs (22 of 29 patients [76%]) injected amphetamine, although most of them 
(97%) used many drugs. Heroin was injected by 13 of 29 addicts (45%), but only two patients 
used cocaine. Ten of 29 IDUs (34%) reported sharing of paraphernalia (e.g., needles, spoons, 
and ﬁ lters) for the drug use.
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Table 10. Characteristics of injection drug users (cases) and nonaddicts (controls) with 
 Staphylococcus aureus bacteremia.
aIncludes only skin colonization before randomization.
bDuring six months preceding the positive blood culture. 
cPrognosis or severity of underlying diseases classiﬁ ed according to the criteria of McCabe and Jackson.
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5.4.2. Clinical manifestations and outcome
There were no differences in the clinical manifestations between IDUs and nonaddicts (n = 88) 
except the more frequent infections due to a central intravenous catheter and a prosthetic device 
among nonaddicts (Article IV: Table 2). The most common infection focus was a skin or a soft 
tissue infection observed in 61 of 88 (61%) patients with no signiﬁ cant difference between the 
patient groups. There was a trend, although it did not reach statistical signiﬁ cance, that a deep 
infection was found more often among IDUs (98%) than in nonaddicts (86%) (p = 0.06). No 
differences were observed in the occurrence of thromboembolic events, duration of fever, serum 
CRP concentration at the time of the ﬁ rst positive blood culture for S. aureus (data not shown), 
or proportion of patients with leukocytosis (data not shown) between IDUs and nonaddicts. 
However, addicts had signiﬁ cantly shorter median duration of hospitalization (31 days) compared 
with nonaddicts (43 days). There were six deaths (two IDUs and four nonaddicts) during three 
months follow-up, all with endocarditis. 
In endocarditis (n = 40), left-sided involvement was signiﬁ cantly more frequent in nonaddicts 
(90%) whereas right-sided endocarditis predominated among addicts (60%) (Article IV: Table 2). 
Septic pulmonary embolism was observed only in addicts. 
5.4.3. Bacterial strains
Among the 87 S. aureus isolates available (one bacterial strain isolated from an addict could not 
be obtained for further analysis), a total of 24 different strain types were detected by PFGE (Table 
11). Seven of the genotypes were similar to known epidemic MRSA types (indicated with FIN-
names), and eight were similar to known MSSA types. Nine strains possessed a sporadic PFGE 
proﬁ le. Of the 19 strains isolated from IDUs with endocarditis, 15 (79%) showed a PFGE proﬁ le 
of a known MRSA genotype. Similarly, among the 24 strains from IDUs without endocarditis, 
17 (71%) strains shared a PFGE proﬁ le of a known MRSA genotype. Among the 20 strains 
from nonaddicts with endocarditis, 11 different PFGE proﬁ les were found (nine MRSA or MSSA 
strain types and two sporadic proﬁ les). Fourteen (70%) strains possessed a known MRSA PFGE 
proﬁ le. The 24 strains isolated from nonaddicts without endocarditis distributed to 11 proﬁ les.  
Bacteremia caused by either a FIN-4 or a FIN-14 strain was more often detected among IDUs 
(42%) than among nonaddicts (18%) (OR 3.24; 95% CI 1.22-8.60; p = 0.02). FIN-4 strain was 
the only single strain observed more frequently in IDUs (21%) than in nonaddicts (5%) (OR 5.56; 
95% CI 1.13-27.46; p = 0.03). No single strain was statistically associated with endocarditis. 
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S. aureus strains (n = 87) isolated from IDUs and nonaddicts were equally often SAK, haemolysin 
and protease producers (Article IV: Table 4). Similarly, there were no differences either in the 
proportion of SAK production, haemolysis and protease activity in endocarditis between IDUs 
and nonaddicts. However, there was a slight trend that haemolytic properties were found more 
often from SAB patients without IE than with IE (79% vs. 59%, respectively; p = 0.06). This 
difference was speciﬁ cally clear among IDUs without endocarditis than with endocarditis (88% 
vs. 47%, respectively; p = 0.007). In contrast, no differences were detected in protease production 
in the above patient groups. The PVL-gene was detected in only two of 87 (2%) strains. Both of 
these were of MSSA8 PFGE proﬁ le; one was observed in an addict without endocarditis, and the 
other in a nonaddict with endocarditis. 
Table 11. Genotypes of Staphylococcus aureus isolates (n = 87) among injection drug users 
 (cases) and nonaddicts (controls) with and without endocarditis. 
 aSigniﬁ cantly more frequent in the 43 injection drug users compared with the 44 nonaddicts (p = 0.03).
 bIncludes PFGE types FIN-3, MSSA1, MSSA3, MSSA8 (PVL+), MSSA10, MSSA11, MSSA14 and MSSA22 
  (1-2 strains each) and sporadic MSSA types (n = 9). 
5.4.4. Serological assays
Serum specimens from 85 patients at acute phase and from 80 patients at convalescent phase 
could be obtained for further analyses. Serum samples from three addicts at acute phase and 
from eight addicts at convalescent phase could not be obtained due to compliance problems. 
A positive ASTA titer was detected at acute phase in 17 of 85 (20%) SAB patients and at 
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convalescent phase in 33 of 80 (41%) patients. Similarly, an initially positive titer for TAA was 
found in 9 of 85 (11%) patients and at convalescent phase in 17 of 80 (21%) patients. The 
combined use of these tests (positive TAA or ASTA at acute or convalescent phase, or 4-fold 
or greater rise in them) increased seropositivity in all SAB patients and in endocarditis (59% vs. 
62%, respectively).
The serological responses of TAA differed between IDUs and nonaddicts (Table 12). TAA titers 
were signiﬁ cantly more often elevated in IDUs than in nonaddicts both at acute phase (OR 10.42; 
95% CI 1.24-87.52; p = 0.01) and at convalescent phase (OR 5.65; 95% CI 1.65-19.39; p = 
0.005). This difference was found especially in endocarditis (Table 12). Interestingly, a positive 
ASTA titer at acute phase was found signiﬁ cantly more frequently among IDUs without IE than 
with IE (44% vs. 6%, respectively; p = 0.01). 
Table 12. Positive serological tests among injection drug users (cases) and nonaddicts (controls)
 in Staphylococcus aureus bacteremia, especially in endocarditis.
ASTA, antistaphylolysin; TAA, teichoic acid antibody; IDUs, injection drug users.
aSigniﬁ cantly more frequent in IDUs compared with nonaddicts (p = 0.01).
bSigniﬁ cantly more frequent in IDUs compared with nonaddicts (p = 0.005).
cSigniﬁ cantly more frequent in endocarditis among IDUs compared with nonaddicts (p = 0.04).
dSigniﬁ cantly more frequent in endocarditis among IDUs compared with nonaddicts (p = 0.01). 
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6. DISCUSSION
6.1. Epidemiology of Staphylococcus aureus bacteremia 
S. aureus is the second most common bloodstream isolate both in hospital and community-
acquired bacteremias in all age groups.42,56,77,382 The epidemiology of SAB has mostly been 
studied in selected hospitals, which may not be representative for the whole population.7,17,44-46 In 
addition, only a few population-based studies, which identify trends in the incidence and outcome 
over time and regions, have previously been published.51 The age- and sex-speciﬁ c incidence 
rates have rarely been reported.48,50-52 Most recent studies have focused on the contribution 
of methicillin resistance to morbidity and mortality associated with SAB.15,49,53,54 However, the 
prevalence of methicillin resistance among S. aureus blood isolates varies widely between 
countries, regions, hospitals and different wards of the same hospital.232,383,384 Population-based 
studies allow comparisons between countries and will provide further insight into the changes in 
the epidemiology of SAB. This might help assessing the impact of the ongoing MRSA epidemic 
occurring worldwide, and give more information on the relative importance of nosocomial and 
community-acquired SAB.51
In Finland, S. aureus bloodstream infections are mostly caused by methicillin-sensitive strains 
and the prevalence of bacteremic MRSA infections has remained low (<3%).90,91 Our nationwide 
population-based study (Study I) demonstrated that the annual incidence of SAB rose signiﬁ cantly 
by 55%, from 11 to 17 cases per 100,000 population during 1995-2001. This incidence is still at a 
lower level than rates previously reported from Denmark and the United States,10,48,50,52 but similar 
to those in the UK, Ireland, and Canada.49,51,53,54 A major increase in SAB rates observed in 
Denmark during 1957-1991, a time period that preceded all the other population-based studies, 
occurred in hospitals while the community-acquired cases remained at almost the same level.48,50 
In the 1990s, the overall SAB incidence in European countries and Canada were of a similar 
magnitude as in our study, but it was double in a metropolitan area in the United States.48-54 
Previously, MRSA has been concluded to contribute signiﬁ cantly to the increase in the overall 
incidence of SAB.44,49 We observed a major increase during a relatively short time period in the 
absence of invasive MRSA. In all other population-based studies, except the one from Canada,51 
the proportion of MRSA out of bacteremic S. aureus infections was considerable, ranging from 
15% to 43% in the 1990s.48-54 
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In addition, rates of SAB may vary because of differences in demographics of the at-risk 
population, blood culture ordering practices, laboratory methods, and use of empirical antibiotic 
therapies. In our study as well as in the previous longitudinal studies from Denmark and the 
UK, the major increase in incidence occurred in the older age group.48-50 In studies with shorter 
observation periods, the highest incidences have been found among males and persons ≥65 
years old,51,52 which were also the biggest patient groups in our nationwide prospective Study II. 
Except for children <1 year old, the risk steadily increased with age in all studies.48-52
Hospital-based studies suggest that rates of both community- and hospital-acquired SAB have 
been increasing44,77,78 although SAB has been predominantly a nosocomial infection over the 
decades.50,52,79-81 In Study I, the proportion of hospital-acquired SAB predominated but remained 
stable over time (Table 3), and was unexpectedly similar to that presented in Study II (54%) and 
in other previous studies (46-53%).8,51,52,385 In our deﬁ nition of nosocomial origin (Study I), we 
presented SAB in recently discharged patients and in patients admitted from other institutions, 
such as nursing homes, from being erroneously classiﬁ ed as community-acquired. Data on SAB 
associated with invasive procedures performed just before or at the time of admission were not 
available. 
Several factors have been suggested for the increase the risk of invasive S. aureus infections. A 
high proportion of patients with SAB generally have one or more underlying diseases.1,51,84,119-121 
Study I did not include data on risk factors or comorbid conditions of patients with SAB. However, 
our nationwide Study II showed that most common underlying diseases were cardiovascular 
diseases (47%), diabetes (27%), chronic lung diseases (19%), chronic renal failure (16%), and 
hepatic cirrhosis (15%) in accordance with earlier reports.1,51,84,119-121
In Study I, we observed temporal and geographic differences in the population-based blood 
culture sampling rates. The rate of blood culture sampling rose by 21%, from 28 blood-culture 
sets to 35 per 1000 population during 1995-2001. Previously, the Danish study reported a 4-fold 
increase in the use of blood cultures from 1957 to 1991.50 In South and West England in 1995, 
blood culture sampling rates varied 2.5-fold between geographic areas, and variations in the 
incidences of invasive pneumococcal disease were largely related to variations in blood culture 
sampling rates.386 The increased incidence of SAB in Study I might be at least due to increased 
reporting. However, it is unlikely that improved reporting accounted for the entire increase, as 
there was an increased incidence in adult age groups in the absence of an increase among 
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children. Furthermore, the increasing trend could be related to increased utilization of blood 
cultures, attributed to a more seriously ill patient population. We did not have data on blood 
cultures processed by age and sex, and therefore we could not assess the relationship between 
blood culture sampling rate and age.
In Study I, case fatality rates were reported at seven days and 28 days, and at three months from 
the ﬁ rst positive blood culture specimen for S. aureus by using data from the National Population 
Registry, but we did not consider the status at discharge (in-house mortality), which might be 
affected by the length of stay and healthcare delivery policies. Overall, 17% of SAB cases died 
within 28 days which is less than the mortality of 23% to 39% generally related to SAB today.1,3,7 
However, a recent nationwide survey from Denmark,10 a country with a very low prevalence 
of MRSA, suggests that mortality in SAB has decreased during 30 years, which might be 
one explanation for the lower case fatality rate in Study I when compared with earlier data. 
Furthermore, a direct comparison of SAB mortality with various reports is complicated by 
inconsistent deﬁ nitions and variable analysis time points. The relatively low mortality rates have 
been based on the deﬁ nition of death within seven days after the onset of SAB (i.e., mortality 
directly attributable to SAB).12,45,221,222 In other studies, higher mortality rates have been reported 
due to longer time period of death within two to ﬁ ve weeks after the onset of bacteremia (i.e., 
in-hospital or overall mortality).3,7,8,120,135 Alterations in case fatality rates suggest the need to 
standardize the mortality end-points. 
In Study I, the mortality was extremely low among children and young adults, but it increased 
with age, being 37% at 28 days among persons aged >74 years. The case fatality rate at 28 days 
for nosocomial cases was almost double than that for community-acquired cases (22% vs. 13%), 
and did not change over time. This could be due to a higher age and probably a more frequent 
prevalence of severe underlying diseases in nosocomial cases. These results are comparable 
with Study II, where the mortality at 28 days increased among older patients (22%) and was 
higher in nosocomial cases than in community-acquired cases (16% vs. 12%). 
The study from Canada also documented the annual mortality rate due to invasive S. aureus 
infections (5/100,000 population per year during 1999-2000).51 The rate is higher than ours 
(4/100,000 per year in 2001), likely due to the fact that their study included all sterile sites and 
we only had bacteremias. We observed an annual increasing trend in SAB mortality rate (2.6 
to 4.2 deaths per 100,000 population during 1995-2001), which has also been reported from 
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England and Wales during 1993-2002.49 However, the UK study was based on death certiﬁ cates, 
and MRSA accounted for most of the increase detected.
The data in the epidemiologic Study I offered a comprehensive assessment of trends and 
outcome of SAB in a well-deﬁ ned population during seven years period, although we did not 
have data on risk factors for acquisition of SAB, underlying conditions, and other complications 
besides death. Interestingly, the changes we detected in the epidemiology of SAB are very 
similar to those found in countries with a high prevalence of MRSA. The increased incidence in 
Finland might be due to a growing population at risk, affected by such factors as high age and 
the prevalence of chronic diseases, and improved survival of patients with severe comorbidity in 
both hospital and non-hospital settings. 
6.2. Effect of antibiotic treatment on outcome in Staphylococcus aureus
 bacteremia
6.2.1. Mortality
S. aureus bacteremia still today confers high mortality and frequent morbidity, although 
antistaphylococcal antibiotics have been available for more than 40 years.3,6,9-14 The possibility of 
MRSA will not have to be considered in Finland when initiating antibiotic treatment. Therefore, 
the standard treatment strategy for bacteremic S. aureus infections is based on a semisynthetic 
penicillin. Data on the effect and recommendations of various antibiotic combinations are 
controversial, although they are widely used in SAB with deep infections. An aminoglycoside 
is combined with standard treatment in endocarditis for 3-14 days, and addition of rifampicin is 
variably used in deep infections or because of poor response to the standard treatment.28,33-35,269 
Some small clinical studies have shown that combination therapy with rifampicin improves clinical 
cure and bacteriological eradication whereas no effect in mortality has been seen.30,31,268,269 
The new treatment options such as newer ﬂ uoroquinolones with improved activity against gram-
positive organisms could be available for severe staphylococcal infections. In experimental 
studies, ﬂ uoroquinolone combined with standard therapy has shown improvement in treatment 
results.38 Because most deep infections are observed within two weeks after the onset of 
bacteremia,39 it was speculated that especially these metastatic infections might be prevented 
by early treatment with bactericidal ﬂ uoroquinolone due to its excellent penetration into tissues. 
Therefore, we conducted the prospective clinical trial (Study II) where efﬁ cacy of levoﬂ oxacin in 
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addition to standard treatment of SAB was studied in relation to patient outcome and development 
of deep infections. Levoﬂ oxacin was chosen since it was the only available ﬂ uoroquinolone with 
enhanced gram-positive activity given both orally and intravenously at that time in Finland. 
Levoﬂ oxacin combination therapy did not decrease mortality nor did it speed up recovery (Table 
6). Overall, 14% of SAB patients died within 28 days in Study II. The low mortality is comparable 
with that observed in recent population-based studies from Finland (Study I) and Denmark,10 but 
clearly higher mortality rates have been reported as discussed above (see section 6.1.).1,3,7 In 
addition, all patients in Study II were followed by an infectious disease specialist, which has been 
shown to improve the outcome and reduce the number of relapses.7,11 Mortality at 28 days in SAB 
(Study II) was highest among patients with ultimately or rapidly fatal disease (27%), endocarditis 
(24%), over 65 years old (22%), deep infection (16%), and hospital-acquired bacteremia (16%) 
in agreement with earlier reports.3,7,14,16,121,145 Interestingly, mortality of patients with a deep 
infection was only 16% although higher mortality rate of 28% has been observed previously.16 
No differences in mortality of these various subgroups could be observed between the antibiotic 
treatment groups (Table 6). 
In Study II, rifampicin was included in the protocol for all patients with deep infection since the 
ultimate aim was to evaluate if levoﬂ oxacin improved treatment results when the best therapy was 
used. Interestingly, if rifampicin was not given mortality was signiﬁ cantly higher than among those 
who received rifampicin (38% vs. 17%). However, this result must be interpreted with caution, 
because the trial was not speciﬁ cally designed to scrutinize the effect of rifampicin. Older age, 
nosocomial bacteremia, and ultimately or rapidly fatal disease by McCabe`s classiﬁ cation were 
associated with higher mortality in patients not receiving rifampicin which has been conﬁ rmed 
generally in previous reports.7,14,65,145 Furthermore, endocarditis and high frequency of deep 
infections were related to poor prognosis.5,7,10,13,16,134 Although these variables occurred more 
often among patients treated with rifampicin, signiﬁ cantly higher mortality was still observed 
among those not treated with rifampicin. In conclusion, patients with a deep infection appeared 
to beneﬁ t from combination treatment with rifampicin, as suggested earlier only by experimental 
data and small clinical studies.30,31,268,269 Thus, we could assume that addition of rifampicin in 
patients with a deep infection might improve outcome, especially in patient groups which are 
generally associated with poor prognosis. 
- 77 -
In the levoﬂ oxacin group there were signiﬁ cantly more patients with a deep infection not treated 
with rifampicin (27%) as compared to the standard treatment group (14%). The reasons for not 
using rifampicin were concomitant liver disease in 15 cases (nine patients in the levoﬂ oxacin 
group vs. six patients in standard treatment group), risk of a drug interaction or other decision 
of the treating physician in 47 cases (31 vs. 16 patients), and an early death of the patients 
in four cases (three vs. one patients). The stratiﬁ ed CMH test was used in order to adjust for 
levoﬂ oxacin as a confounding factor when the effect of rifampicin was analyzed. In patients 
with deep infection receiving rifampicin, a trend towards lower mortality (13%) was observed 
in the levoﬂ oxacin group as compared to the standard treatment group (20%). This difference, 
however, was not statistically signiﬁ cant. The data indicate that a ﬂ uoroquinolone could not be 
recommended to be combined with the standard treatment of SAB. As the present study design 
did not directly compare levoﬂ oxacin to rifampicin, the potential beneﬁ t of levoﬂ oxacin when 
rifampicin cannot be used remains to be shown in further prospective studies. If ﬂ uoroquinolones 
could be useful in MRSA bacteremias cannot be answered by this trial, because bacteremias 
due to MRSA were not included. Resistance to ﬂ uoroquinolones has increased among MRSA 
strains,95 why they, however, might not offer a good therapeutic alternative for the treatment of 
MRSA infections.292 
6.2.2. Clinical manifestations 
Study II provides many unique features: the prospective design for three years in 12 Finnish 
hospitals, worldwide one of the largest population of SAB patients, and comprehensive data 
of antibiotic treatment, clinical manifestations and outcome of SAB in area with a very low 
prevalence of methicillin resistance. The initial infection focus for SAB is most often skin or soft 
tissue infection which was observed in two thirds of all patients during the three months follow-up 
in Study II. However, the clinical impact of SAB is determined by its complications, particularly 
by the development of deep infections due to metastatic spread, and by high recurrence rate 
of bacteremia.1,3-7 The reported frequency of metastatic infections varies widely, from 10% to 
53%,9,16,84,121,145 but it was even 87% in Study II. This difference might be partly explained by 
different deﬁ nitions between studies as well as by the high intensity search for deep infections 
in our study. Furthermore, in most articles the incidence of deep infections have not been 
separately reported or they have been classiﬁ ed into primary and secondary foci (i.e., metastatic 
infections).7,17,121,123,128,138 
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In Study II, infection foci were analyzed according to whether observed before or later than one 
week after randomization predicted the effectiveness of levoﬂ oxacin therapy as compared to 
the standard treatment (Table 5). Most of the deep infections (84%) were diagnosed within one 
week after randomization. In another recent study,16 74% of metastatic infections were already 
present at the time of hospitalization in accordance with our ﬁ ndings. Thus, these data suggest 
that infection foci cannot reliably be classiﬁ ed as primary or metastatic. In addition, there was no 
signiﬁ cant difference in the formation of new deep infections after the ﬁ rst week of randomization 
between the treatment groups. This might be one reason why levoﬂ oxacin combination therapy 
did not decrease the incidence of deep infections which was one of the main objectives for the 
study. 
Intravenous antibiotic treatment is recommended for four to six weeks in SAB with a deep 
infection.76,86 In Study II, the duration of parenteral and oral antibiotic therapy was much more 
prolonged due to high incidence of deep infections, and extended with an average of 77 days. Of 
all patients, 44% remained on antibiotic treatment at three months. This may have contributed to 
the low (1%) prevalence of SAB recurrences (three patients with relapse and two with reinfection). 
Signiﬁ cantly higher recurrence rates from 9% to 23%, have been reported in studies with slightly 
longer follow-up times from three to six months.6,8,11,13,16,65,235
Our study suggests that when SAB occurs, identiﬁ cation of deep infections might be essential 
for decreased mortality, and therapeutic approach including focus eradication and prolonged 
parenteral therapy with deep infections are warranted. 
6.3. Endocarditis 
6.3.1. Predisposing factors and underlying conditions for endocarditis 
S. aureus is a leading cause of bacteremia and infective endocarditis (IE) in many regions of the 
world.18,21,76,126 During recent decades IE has been observed in 11% to 35% of SAB attributable 
to different sets of diagnostic criteria.65-68 In agreement with previous data, the incidence of 
endocarditis was 17% of all SAB patients in Study III. Changes in the epidemiology of IE have 
emerged. Classic risk factors such as rheumatic heart disease are being replaced by new ones, 
including IDUs, elderly patients with degenerative valve disease, patients with intravascular 
catheter or prosthetic valve, mitral valve prolapse, prior IE, and nosocomial acquisition.22,79,126 This 
was also conﬁ rmed in Study III, despite that S. aureus endocarditis was primarily community-
acquired in 54% of patients as reported earlier.84,123
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S. aureus endocarditis presents as two distinct patient groups, IDUs and nonaddicts, depending 
on the different location of infection, and differences in clinical manifestations and prognosis.120 
The incidence of endocarditis in SAB varies between 35% to 67% among IDUs.65,69-72 IE was 
found in 46% of IDUs in our study (Study III). Among patients with SAB and endocarditis 
(Studies III and IV), IDUs as a group were signiﬁ cantly younger, had less predisposing heart 
conditions or severe underlying diseases by McCabe`s classiﬁ cation,377 and had more often 
community-acquired bacteremia as published previously.19,71,145,157,179,208,358,387 Furthermore, IDUs 
had signiﬁ cantly more often pre-existing liver disease (mainly chronic hepatitis C infection) than 
nonaddicts, but despite that none of the addicts had an abnormal ALT elevation during the three 
months follow-up. 
The reasons for the high occurrence of S. aureus endocarditis among IDUs are largely unknown. 
Factors that seem to contribute to an increased prevalence of staphylococcal disease in addicts 
include the pathogen, the host, the drugs (e.g., heroin or cocaine), the drug-use environment, and 
drug using habits.126 The source of S. aureus may be endogenous (the drug user´s own ﬂ ora) or 
external (contaminated drugs, drug adulterants, or paraphernalia).182,183,208,388 However, previous 
S. aureus deep infection or bacteremia before the randomization was not associated with the 
present SAB or endocarditis among IDUs (Studies III and IV). Prior S. aureus colonization of the 
skin was signiﬁ cantly more often observed in nonaddicts than among IDUs (Study IV) which is 
in contrast with previous data.111,112
6.3.2. Site of endocarditis and clinical manifestations 
S. aureus endocarditis is associated with a higher occurrence of extracardiac deep infections 
due to metastatic spread and thromboembolic events compared with IE caused by other 
pathogens.18,21 The differences between IDUs and the general population have been derived 
from non-comparative trials, and there are only a few studies where the clinical picture of S. 
aureus endocarditis in these patient groups has been compared.19,21,189,224 Therefore, we collected 
prospectively one of the largest SAB population with endocarditis comparing patients with and 
without injection drug abuse (Studies III and IV). The lack of MRSA might complicate extrapolation 
of these results into countries with a high MRSA prevalence. However, MRSA endocarditis is 
usually more difﬁ cult to treat. While concentrating only on cases by MSSA strains real differences 
between IDUs and nonaddicts might be better revealed. 
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The proportion of deﬁ nite IE (76%) in Study III (Table 8) was in line with that observed in the other 
large survey.65 Frequent use of echocardiography may increase the incidence of endocarditis at 
least to some extent. In our study, echocardiography was performed as clinically indicated. It was 
done to 61% of SAB patients (Study III) and the rate was similar or higher compared with other 
studies.7,16,189 Some endocarditis cases with an atypical presentation might have been missed 
because echocardiography in our cohort as well as in previous studies was not performed for all 
SAB patients. 
In Study III, the tricuspid valve was predominantly affected in addicts (60%), although the 
incidence was slightly lower than that reported previously (from 70% to 90%) (Table 8).19,79,189,193 
Furthermore, the frequency of left-sided involvement in addicts was as high as 30% which is 
similar to that observed in other studies,64,79,196 but higher than in most earlier reports with left-
sided endocarditis ranging from 8% to 19%.71,186,193 In IDUs, both sides of the heart are usually 
involved simultaneously in 5% to 10% of cases as detected also in our trial. 
The increased risk of soft tissue abscesses has been related to the use of a cocaine and heroin 
mixture.63,111,388 In Study IV, most IDUs had injected amphetamine and only two patients had used 
cocaine. This suggests that the risk for soft tissue infections might not be associated with the 
abused drug but rather to the injection mode of use. Extracardiac deep infections are generally 
observed in left-sided endocarditis with an incidence of 40% to 76%.12,69,164 In contrast to previous 
studies,19,71,145 extracardiac deep infections occurred in over 80% in both IDUs and nonaddicts 
(Studies III and IV). Systemic thromboembolic events are generally found in 21% to 50% of 
patients in endocarditis168-170,172 and they are related especially to left-sided involvement and 
prosthetic heart valves with high mortality rates. In earlier reports, IDUs had fewer arterial 
emboli or strokes than nonaddicts probably due to involvement of right-sided endocarditis.21,185,197 
In contrast, we observed arterial thromboembolic events equally often among addicts and 
nonaddicts (Studies III and IV). Venous embolic events were even more common in IDUs, 
and septic pulmonary embolism manifestated only in IDUs. However, the frequency of septic 
pulmonary embolism (40%) was less than the previously reported incidence of 67% to 87% 
among addicts.185,194,195 Recurrent endocarditis is frequently seen in IDUs, and the median 
intervals between episodes is far shorter in addicts compared with nonaddicts.170
The duration of antibiotic treatment in SAB depends largely on the presence of an associated 
IE, in which four to six weeks therapy is recommended.27,86,157 A shorter two weeks treatment 
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has been suggested for selected cases of right-sided involvement with a good prognosis.27,389 
However, the high proportion of extracardiac deep infections among addicts extended the 
intravenous antibiotic therapy to four weeks (Study III). This observation suggests that deep 
infections should be actively searched for also in IDUs. 
6.3.3. Mortality in endocarditis
The overall mortality in S. aureus endocarditis is high, ranging between 30% to 71% according 
to various data.18,60,65,66,124,143,224 In Study III, a lower mortality (23%) at 28 days was found in 
endocarditis due to SAB (Table 9). Mortality at three months was also only 31%. The prognosis 
of staphylococcal endocarditis among IDUs tends to be better than in nonaddicts, with mortality 
rate varying between 2% and 12%.19-21 This was also conﬁ rmed in our study (Study III), where the 
mortality for IDUs with endocarditis was only 5% whereas 30% of nonaddicts deceased (Table 9). 
Fatal outcome in S. aureus endocarditis has been associated with older age, rapidly fatal underlying 
diseases, pre-existing heart valve diseases, presence of a prosthetic valve, severe sepsis, 
left-sided involvement, CNS events, heart failure, absence of surgical therapy, and persistent 
bacteremia.7,18,21,65,68,189,224,225 In contrast, host factors such as younger age and lack of severe 
underlying diseases in addicts have been associated with favourable prognosis,19,21,157,224 which 
was also observed in Study III. Furthermore, the reason for better outcome in addicts has been 
partly explained by observations in experimental right-sided endocarditis.226,227,390,391 Spontaneous 
sterilization of valve vegetations were detected more often in the right side of heart and the density 
of bacteria in infected tricuspid vegetations was smaller than in left-sided valves. Study III showed 
the tendency for lower mortality in patients with right-sided IE but for higher mortality in patients 
with severe sepsis, left-sided involvement, and arterial embolic events. However, these factors did 
not achieve statistical signiﬁ cance probably due to insufﬁ cient sample size. 
There is no single hypothesis to explain why addicts have better outcome than nonaddicts in 
S. aureus endocarditis. The ﬁ ndings of an equal number of extracardiac deep infections and 
vascular phenomena among IDUs (Studies III and IV) makes it even more difﬁ cult to ﬁ nd an 
explanation. However, we showed that injection drug abuse in accordance with younger age 
and lack of severe underlying diseases were associated with better prognosis as published 
previously. In addition, a favourable outcome in Study III could have been due to an intensive 
search for extracardiac deep infections which led to prolonged intravenous antibiotic therapy also 
in addicts. 
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6.3.4. Bacterial strain characteristics and serological assays
Outbreaks due to a single S. aureus strain have been reported in addicts.183,349 In Study IV, FIN-4 
strain was the only single strain observed signiﬁ cantly more frequently among IDUs as compared 
to nonaddicts, but no epidemic clone was detected (Table 11). The other strain that slightly 
dominated among IDUs was FIN-14 and when analyzed together with FIN-4 they were found 
more often among IDUs than among nonaddicts. The similar strains have previously been related 
to community-acquired MRSA infections.353 However, bacteremia and endocarditis among IDUs 
were caused by many various strains and these strains were commonly found among nonaddicts 
as well (Study IV). Therefore, no individual strain dominated as an etiologic agent for endocarditis 
in either patient groups.
It has been speculated that frequent encounter with a microbe, or bacterial strain characteristics 
play a role in the development of endocarditis, and also possibly a more prevalent serologic 
response among IDUs. Staphylokinase (SAK) production is connected to an uncomplicated 
bacteremia and a better prognosis.333 SAK has been suggested to be part of the adaptive 
mechanisms of S. aureus favoring bacterial symbiosis with the host or preventing defence 
mechanisms of the host. These hypotheses were not supported by the present Study IV, because 
SAK expression could be demonstrated in 87% of all strains, and even in 92% of strains 
associated with deep infections (i.e., complicated SAB). There were neither any signiﬁ cant 
differences in the ratios of protease production among strains originating from various patient 
groups. Interestingly, although there was no differences in haemolysin production between strains 
from IDUs and nonaddicts, haemolytic properties were found signiﬁ cantly more frequently in 
strains from IDUs without endocarditis than with endocarditis (88% vs. 47%). It would be possible 
that S. aureus strains without haemolytic activity might predispose to endocarditis in addicts. This 
ﬁ nding warrants further studies.
S. aureus strains producing Panton-Valentine leukocidin (PVL) are related to community-acquired 
skin infections and severe pulmonary manifestations in children and young adults.209,339,392 We 
observed in Study IV, that majority of isolates (98%) were PVL-negative although two thirds of 
the IDUs and nonaddicts had a skin or a soft tissue infection. Our results are in accordance 
with a previous report, in which PLV was neither associated with deep infections such as 
endocarditis.209
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Classical serological markers for S. aureus infections are antibody levels against α-haemolysin 
(ASTA) and ribitol teichoic acid (TAA). In earlier reports, the elevated TAA values were seen in 
SAB with metastatic infections such as endocarditis.69,250,357,366 ASTA is considered to be of limited 
value due to its low sensitivity. High titers of ASTA have been found in staphylococcal patients 
with various dermatoses, particularly in atopic dermatitis.373,374 According to Study IV, TAA and 
ASTA were not helpful in identifying deep infections in SAB because only a small proportion of 
patients developed a positive serological response. However, positive TAA titers during the acute 
phase of bacteremia were found among addicts, especially in IE. Furthermore, half of the IDUs 
with endocarditis had a positive TAA titer also at the convalescent phase. Thus, this serological 
response most probably was due to previous and recurrent intravenous exposure to S. aureus in 
agreement with earlier reports.362,368
Interestingly, we detected an elevated initial ASTA titer signiﬁ cantly more often among IDUs 
without endocarditis than with endocarditis (44% vs. 6%). The same patient group also displayed 
a higher percentage of elevated ASTA titers during the course of the disease. These ﬁ ndings 
support the idea that addicts frequently “vaccinate” themselves with S. aureus creating an 
antibody response against α-haemolysin which in turn might protect from endocarditis and give 
better prognosis in SAB. 
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7. SUMMARY AND CONCLUSIONS
 
The main results of the present study can be summarized:
I  The annual incidence of SAB in Finland during 1995-2001 increased in our retrospective 
epidemiologic study. Increased incidence was especially observed in elderly people. While 
the increase in incidence may partly be explained by better reporting, it most likely reﬂ ects 
a growing population at risk, affected by such factors as age and/or severe comorbidity. 
Nosocomial infections accounted for 51% of cases during the study period. The 28-day 
mortality, remaining unchanged at 17% throughout the 7-year follow-up, was lower than 
reported in previous surveys. The risk of death for nosocomial cases was almost double 
than that for community-acquired cases (22% vs. 13%). Interestingly, the changes in the 
epidemiology of SAB are very similar to those found in countries with high prevalence of 
MRSA.
II  Levoﬂ oxacin, combined with standard treatment, did not decrease the mortality, lower the 
incidence of deep infections, nor did it speed up the recovery in SAB. However, mortality 
for patients with deep infection was signiﬁ cantly lower among those who received rifampicin 
as compared to those treated without rifampicin (17% vs. 38%), as suggested earlier by 
experimental data and some small clinical trials. Deep infections were found in 84% of SAB 
patients within one week after randomization, and they appeared to be more common than 
previously reported in other studies. Prompt identiﬁ cation of deep infections might improve 
the outcome of these patients. 
III  Endocarditis was more frequently connected to SAB in addicts as has also been reported 
previously. Additionally, IDUs were signiﬁ cantly younger, had less ultimately or rapidly 
fatal underlying diseases or predisposing heart diseases, and their SAB was more often 
community-acquired as compared to nonaddicts. Right-sided involvement was diagnosed in 
60% of addicts whereas 93% of nonaddicts had left-sided endocarditis. Unexpectedly, IDUs 
showed extracardiac deep infections, thromboembolic events and severe sepsis with the 
same frequency as nonaddicts. The prognosis of endocarditis was better among injection 
drug abusers due to their younger age and lack of underlying diseases, as suggested 
previously. 
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IV  No individual S. aureus strain was speciﬁ cally associated with endocarditis among addicts. 
In addition, characterization of the virulence factors did not reveal a difference between 
IDUs and nonaddicts. However, haemolytic properties were observed more often among 
IDUs without endocarditis than with endocarditis. Serological tests were not helpful in 
identifying patients with a deep infection. Interestingly, the initial ASTA titer was more often 
positive among IDUs without endocarditis than those with endocarditis. One may postulate 
that among addicts strains without haemolytic activity could predispose to endocarditis, 
whereas an antibody response against staphylolysin might give some protection from it.
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